Search

Your search keyword '"Kümler, Thomas"' showing total 147 results
Start Over Author "Kümler, Thomas"
147 results on '"Kümler, Thomas"'

3. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

Author

Abban, Dzifa Wosornu, Abdul, Nasser, Abud, Atilio Marcelo, Adams, Fran, Addala, Srinivas, Adragão, Pedro, Ageno, Walter, Aggarwal, Rajesh, Agosti, Sergio, Agostoni, Piergiuseppe, Aguilar, Francisco, Linares, Julio Aguilar, Aguinaga, Luis, Ahmed, Jameel, Aiello, Allessandro, Ainsworth, Paul, Aiub, Jorge Roberto, Al-Dallow, Raed, Alderson, Lisa, Aldrete Velasco, Jorge Antonio, Alexopoulos, Dimitrios, Manterola, Fernando Alfonso, Aliyar, Pareed, Alonso, David, Alves da Costa, Fernando Augusto, Amado, José, Amara, Walid, Amelot, Mathieu, Amjadi, Nima, Ammirati, Fabrizio, Andrade, Marianna, Andrawis, Nabil, Annoni, Giorgio, Ansalone, Gerardo, Ariani, M.Kevin, Arias, Juan Carlos, Armero, Sébastien, Arora, Chander, Aslam, Muhammad Shakil, Asselman, M., Audouin, Philippe, Augenbraun, Charles, Aydin, S., Ayryanova, Ivaneta, Aziz, Emad, Backes, Luciano Marcelo, Badings, E., Bagni, Ermentina, Baker, Seth H., Bala, Richard, Baldi, Antonio, Bando, Shigenobu, Banerjee, Subhash, Bank, Alan, Esquivias, Gonzalo Barón, Barr, Craig, Bartlett, Maria, Kes, Vanja Basic, Baula, Giovanni, Behrens, Steffen, Bell, Alan, Benedetti, Raffaella, Mazuecos, Juan Benezet, Benhalima, Bouziane, Bergler-Klein, Jutta, Berneau, Jean-Baptiste, Bernstein, Richard A., Berrospi, Percy, Berti, Sergio, Berz, Andrea, Best, Elizabeth, Bettencourt, Paulo, Betzu, Robert, Bhagwat, Ravi, Bhatta, Luna, Biscione, Francesco, Bisignani, Giovanni, Black, Toby, Bloch, Michael J., Bloom, Stephen, Blumberg, Edwin, Bo, Mario, Bøhmer, Ellen, Bollmann, Andreas, Bongiorni, Maria Grazia, Boriani, Giuseppe, Boswijk, D.J., Bott, Jochen, Bottacchi, Edo, Kalan, Marica Bracic, Bradman, Drew, Brautigam, Donald, Breton, Nicolas, Brouwers, P.J.A.M., Browne, Kevin, Cortada, Jordi Bruguera, Bruni, A., Brunschwig, Claude, Buathier, Hervé, Buhl, Aurélie, Bullinga, John, Cabrera, Jose Walter, Caccavo, Alberto, Cai, Shanglang, Caine, Sarah, Calò, Leonardo, Calvi, Valeria, Sánchez, Mauricio Camarillo, Candeias, Rui, Capuano, Vincenzo, Capucci, Alessandro, Caputo, Ronald, Rizo, Tatiana Cárdenas, Cardona, Francisco, Carlos da Costa Darrieux, Francisco, Duarte Vera, Yan Carlos, Carolei, Antonio, Carreño, Susana, Carvalho, Paula, Cary, Susanna, Casu, Gavino, Cavallini, Claudio, Cayla, Guillaume, Celentano, Aldo, Cha, Tae-Joon, Cha, Kwang Soo, Chae, Jei Keon, Chalamidas, Kathrine, Challappa, Krishnan, Chand, Sunil Prakash, Chandrashekar, Harinath, Chartier, Ludovic, Chatterjee, Kausik, Chavez Ayala, Carlos Antero, Cheema, Aamir, Cheema, Amjad, Chen, Lin, Chen, Shih-Ann, Chen, Jyh Hong, Chiang, Fu-Tien, Chiarella, Francesco, Chih-Chan, Lin, Cho, Yong Keun, Choi, Jong-Il, Choi, Dong Ju, Chouinard, Guy, Hoi-Fan Chow, Danny, Chrysos, Dimitrios, Chumakova, Galina, José Roberto, Eduardo Julián, Valenzuela, Chuquiure, Nica, Nicoleta Cindea, Cislowski, David J., Clay, Anthony, Clifford, Piers, Cohen, Andrew, Cohen, Michael, Cohen, Serge, Colivicchi, Furio, Collins, Ronan, Colonna, Paolo, Compton, Steve, Connolly, Derek, Conti, Alberto, Buenostro, Gabriel Contreras, Coodley, Gregg, Cooper, Martin, Coronel, Julian, Corso, Giovanni, Sales, Juan Cosín, Cottin, Yves, Covalesky, John, Cracan, Aurel, Crea, Filippo, Crean, Peter, Crenshaw, James, Cullen, Tina, Darius, Harald, Dary, Patrick, Dascotte, Olivier, Dauber, Ira, Davalos, Vicente, Davies, Ruth, Davis, Gershan, Davy, Jean-Marc, Dayer, Mark, De Biasio, Marzia, De Bonis, Silvana, De Caterina, Raffaele, De Franceschi, Teresiano, de Groot, J.R., De Horta, José, De La Briolle, Axel, Topete, Gilberto de la Pena, Vicenzo de Paola, Angelo Amato, de Souza, Weimar, de Veer, A., De Wolf, Luc, Decoulx, Eric, Deepak, Sasalu, Defaye, Pascal, Del-Carpio Munoz, Freddy, Brkljacic, Diana Delic, Deumite, N. Joseph, Di Legge, Silvia, Diemberger, Igor, Dietz, Denise, Dionísio, Pedro, Dong, Qiang, Rossi dos Santos, Fabio, Dotcheva, Elena, Doukky, Rami, D'Souza, Anthony, Dubrey, Simon, Ducrocq, Xavier, Dupljakov, Dmitry, Duque, Mauricio, Dutta, Dipankar, Duvilla, Nathalie, Duygun, A., Dziewas, Rainer, Eaton, Charles B., Eaves, William, Ebels-Tuinbeek; Clifford Ehrlich, L.A., Eichinger-Hasenauer, Sabine, Eisenberg, Steven J., El Jabali, Adnan, El Shahawy, Mahfouz, Hernandes, Mauro Esteves, Izal, Ana Etxeberria, Evonich, Rudolph, III, Evseeva, Oksana, Ezhov, Andrey, Fahmy, Raed, Fang, Quan, Farsad, Ramin, Fauchier, Laurent, Favale, Stefano, Fayard, Maxime, Fedele, Jose Luis, Fedele, Francesco, Fedorishina, Olga, Fera, Steven R., Gomes Ferreira, Luis Gustavo, Ferreira, Jorge, Ferri, Claudio, Ferrier, Anna, Ferro, Hugo, Finsen, Alexandra, First, Brian, Fischer, Stuart, Fonseca, Catarina, Almeida, Luísa Fonseca, Forman, Steven, Frandsen, Brad, French, William, Friedman, Keith, Friese, Athena, Fruntelata, Ana Gabriela, Fujii, Shigeru, Fumagalli, Stefano, Fundamenski, Marta, Furukawa, Yutaka, Gabelmann, Matthias, Gabra, Nashwa, Gadsbøll, Niels, Galinier, Michel, Gammelgaard, Anders, Ganeshkumar, Priya, Gans, Christopher, Quintana, Antonio Garcia, Gartenlaub, Olivier, Gaspardone, Achille, Genz, Conrad, Georger, Frédéric, Georges, Jean-Louis, Georgeson, Steven, Giedrimas, Evaldas, Gierba, Mariusz, Ortega, Ignacio Gil, Gillespie, Eve, Giniger, Alberto, Giudici, Michael C., Gkotsis, Alexandros, Glotzer, Taya V., Gmehling, Joachim, Gniot, Jacek, Goethals, Peter, Goldbarg, Seth, Goldberg, Ronald, Goldmann, Britta, Golitsyn, Sergey, Gómez, Silvia, Mesa, Juan Gomez, Gonzalez, Vicente Bertomeu, Gonzalez Hermosillo, Jesus Antonio, González López, Víctor Manuel, Gorka, Hervé, Gornick, Charles, Gorog, Diana, Gottipaty, Venkat, Goube, Pascal, Goudevenos, Ioannis, Graham, Brett, Greer, G. Stephen, Gremmler, Uwe, Grena, Paul G., Grond, Martin, Gronda, Edoardo, Grönefeld, Gerian, Gu, Xiang, Torres Torres, Ivett Guadalupe, Guardigli, Gabriele, Guevara, Carolina, Guignier, Alexandre, Gulizia, Michele, Gumbley, Michael, Günther, Albrecht, Ha, Andrew, Hahalis, Georgios, Hakas, Joseph, Hall, Christian, Han, Bing, Han, Seongwook, Hargrove, Joe, Hargroves, David, Harris, Kenneth B., Haruna, Tetsuya, Hayek, Emil, Healey, Jeff, Hearne, Steven, Heffernan, Michael, Heggelund, Geir, Heijmeriks, J.A., Hemels, Maarten, Hendriks, I., Henein, Sam, Her, Sung-Ho, Hermany, Paul, Hernández Del Río, Jorge Eduardo, Higashino, Yorihiko, Hill, Michael, Hisadome, Tetsuo, Hishida, Eiji, Hoffer, Etienne, Hoghton, Matthew, Hong, Kui, Hong, Suk keun, Horbach, Stevie, Horiuchi, Masataka, Hou, Yinglong, Hsing, Jeff, Huang, Chi-Hung, Huckins, David, Hughes, kathy, Huizinga, A., Hulsman, E.L., Hung, Kuo-Chun, Hwang, Gyo-Seung, Ikpoh, Margaret, Imberti, Davide, Ince, Hüseyin, Indolfi, Ciro, Inoue, Shujiro, Irles, Didier, Iseki, Harukazu, Israel, C. Noah, Iteld, Bruce, Iyer, Venkat, Jackson-Voyzey, Ewart, Jaffrani, Naseem, Jäger, Frank, James, Martin, Jang, Sung-Won, Jaramillo, Nicolas, Jarmukli, Nabil, Jeanfreau, Robert J., Jenkins, Ronald D., Sánchez, Carlos Jerjes, Jimenez, Javier, Jobe, Robert, Joen-Jakobsen, Tomas, Jones, Nicholas, Moura Jorge, Jose Carlos, Jouve, Bernard, Jung, Byung Chun, Jung, Kyung Tae, Jung, Werner, Kachkovskiy, Mikhail, Kafkala, Krystallenia, Kalinina, Larisa, Kallmünzer, Bernd, Kamali, Farzan, Kamo, Takehiro, Kampus, Priit, Kashou, Hisham, Kastrup, Andreas, Katsivas, Apostolos, Kaufman, Elizabeth, Kawai, Kazuya, Kawajiri, Kenji, Kazmierski, John F., Keeling, P., Kerr Saraiva, José Francisco, Ketova, Galina, Khaira, Ajit Singh, Khripun, Aleksey, Kim, Doo-Il, Kim, Young Hoon, Kim, Nam Ho, Kim, Dae Kyeong, Kim, Jeong Su, Kim, June Soo, Kim, Ki Seok, Kim, Jin bae, Kinova, Elena, Klein, Alexander, Kmetzo, James J., Kneller, G. Larsen, Knezevic, Aleksandar, Angela Koh, Su Mei, Koide, Shunichi, Kollias, Anastasios, Kooistra, J.A., Koons, Jay, Koschutnik, Martin, Kostis, William J., Kovacic, Dragan, Kowalczyk, Jacek, Koziolova, Natalya, Kraft, Peter, Kragten, Johannes A., Krantz, Mori, Krause, Lars, Krenning, B.J., Krikke, F., Kromhout, Z., Krysiak, Waldemar, Kumar, Priya, Kümler, Thomas, Kuniss, Malte, Kuo, Jen-Yuan, Küppers, Achim, Karla Kurrelmeyer, Kwak, Choong Hwan, Laboulle, Bénédicte, Labovitz, Arthur, Lai, Wen Ter, Lam, Andy, Lam, Yat Yin, Zanetti, Fernando Lanas, Landau, Charles, Landini, Giancarlo, Figueiredo, Estêvão Lanna, Larsen, Torben, Lavandier, Karine, LeBlanc, Jessica, Lee, Moon Hyoung, Lee, Chang-Hoon, Lehman, John, Leitão, Ana, Lellouche, Nicolas, Lelonek, Malgorzata, Lenarczyk, Radoslaw, Lenderink, T., González, Salvador León, Leong-Sit, Peter, Leschke, Matthias, Ley, Nicolas, Li, Zhanquan, Li, Xiaodong, Li, Weihua, Li, Xiaoming, Lichy, Christhoh, Lieber, Ira, Limon Rodriguez, Ramon Horacio, Lin, Hailong, Lip, Gregory Y.H., Liu, Feng, Liu, Hengliang, Esperon, Guillermo Llamas, Navarro, Nassip Llerena, Lo, Eric, Lokshyn, Sergiy, López, Amador, López-Sendón, José Luís, Lorga Filho, Adalberto Menezes, Lorraine, Richard S., Luengas, Carlos Alberto, Luke, Robert, Luo, Ming, Lupovitch, Steven, Lyrer, Philippe, Ma, Changsheng, Ma, Genshan, Madariaga, Irene, Maeno, Koji, Magnin, Dominique, Maid, Gustavo, Mainigi, Sumeet K., Makaritsis, Konstantinos, Malhotra, Rohit, Manning, Rickey, Manolis, Athanasios, Manrique Hurtado, Helard Andres, Mantas, Ioannis, Jattin, Fernando Manzur, Maqueda, Vicky, Marchionni, Niccolo, Ortuno, Francisco Marin, Santana, Antonio Martín, Martinez, Jorge, Maskova, Petra, Hernandez, Norberto Matadamas, Matsuda, Katsuhiro, Maurer, Tillmann, Mauro, Ciro, May, Erik, Mayer, Nolan, McClure, John, McCormack, Terry, McGarity, William, McIntyre, Hugh, McLaurin, Brent, Medina Palomino, Feliz Alvaro, Melandri, Francesco, Meno, Hiroshi, Menzies, Dhananjai, Mercader, Marco, Meyer, Christian, Meyer, Beat J., Miarka, Jacek, Mibach, Frank, Michalski, Dominik, Michel, Patrik, Chreih, Rami Mihail, Mikdadi, Ghiath, Mikus, Milan, Milicic, Davor, Militaru, Constantin, Minaie, Sedi, Minescu, Bogdan, Mintale, Iveta, Mirault, Tristan, Mirro, Michael J., Mistry, Dinesh, Miu, Nicoleta Violeta, Miyamoto, Naomasa, Moccetti, Tiziano, Mohammed, Akber, Nor, Azlisham Mohd, Mollerus, Michael, Molon, Giulio, Mondillo, Sergio, Moniz, Patrícia, Mont, Lluis, Montagud, Vicente, Montaña, Oscar, Monti, Cristina, Moretti, Luciano, Mori, Kiyoo, Moriarty, Andrew, Morka, Jacek, Moschini, Luigi, Moschos, Nikitas, Mügge, Andreas, Mulhearn, Thomas J., Muresan, Carmen, Muriago, Michela, Musial, Wlodzimierz, Musser, Carl W., Musumeci, Francesco, Nageh, Thuraia, Nakagawa, Hidemitsu, Nakamura, Yuichiro, Nakayama, Toru, Nam, Gi-Byoung, Nanna, Michele, Natarajan, Indira, Nayak, Hemal M., Naydenov, Stefan, Nazlić, Jurica, Cristian Nechita, Alexandru, Nechvatal, Libor, Negron, Sandra Adela, Neiman, James, Neuenschwander, Fernando Carvalho, Neves, David, Neykova, Anna, Miguel, Ricardo Nicolás, Nijmeh, George, Nizov, Alexey, Campos, Rodrigo Noronha, Nossan, Janko, Novikova, Tatiana, Nowalany-Kozielska, Ewa, Nsah, Emmanuel, Nunez Fragoso, Juan Carlos, Nurgalieva, Svetlana, Nuyens, Dieter, Nyvad, Ole, Odin de Los Rios Ibarra, Manuel, O'Donnell, Philip, O'Donnell, Martin, Oh, Seil, Oh, Yong Seog, Oh, Dongjin, O'Hara, Gilles, Oikonomou, Kostas, Olivares, Claudia, Oliver, Richard, Ruiz, Rafael Olvera, Olympios, Christoforos, omaszuk-Kazberuk, Anna, Asensi, Joaquín Osca, Jose, eena Padayattil, Padilla Padilla, Francisco Gerardo, Rios, Victoria Padilla, Pajes, Giuseppe, Pandey, Shekhar, Paparella, Gaetano, Paris, F., Park, Hyung Wook, Park, Jong Sung, Parthenakis, Fragkiskos, Passamonti, Enrico, Patel, Rajesh J., Patel, Jaydutt, Patel, Mehool, Patrick, Janice, Jimenez, Ricardo Pavón, Paz, Analía, Pengo, Vittorio, Pentz, William, Pérez, Beatriz, Pérez Ríos, Alma Minerva, Pérez-Cabezas, Alejandro, Perlman, Richard, Persic, Viktor, Perticone, Francesco, Peters, Terri K., Petkar, Sanjiv, Pezo, Luis Felipe, Pflücke, Christian, Pham, David N., Phillips, Roland T., Phlaum, Stephen, Pieters, Denis, Pineau, Julien, Pinter, Arnold, Pinto, Fausto, Pisters, R., Pivac, Nediljko, Pocanic, Darko, Podoleanu, Cristian, Politano, Alessandro, Poljakovic, Zdravka, Pollock, Stewart, Garcéa, Jose Polo, Poppert, Holger, Porcu, Maurizio, Reino, Antonio Pose, Prasad, Neeraj, Précoma, Dalton Bertolim, Prelle, Alessandro, Prodafikas, John, Protasov, Konstantin, Pye, Maurice, Qiu, Zhaohui, Quedillac, Jean-Michel, Raev, Dimitar, Raffo Grado, Carlos Antonio, Rahimi, Sidiqullah, Raisaro, Arturo, Rama, Bhola, Ramos, Ricardo, Ranieri, Maria, Raposo, Nuno, Rashba, Eric, Rauch-Kroehnert, Ursula, Reddy, Ramakota, Renda, Giulia, Reza, Shabbir, Ria, Luigi, Richter, Dimitrios, Rickli, Hans, Rieker, Werner, Vera, Tomas Ripolil, Ritt, Luiz Eduardo, Roberts, Douglas, Briones, Ignacio Rodriguez, Rodriguez Escudero, Aldo Edwin, Pascual, Carlos Rodríguez, Roman, Mark, Romeo, Francesco, Ronner, E., Roux, Jean-Francois, Rozkova, Nadezda, Rubacek, Miroslav, Rubalcava, Frank, Russo, Andrea M., Rutgers, Matthieu Pierre, Rybak, Karin, Said, Samir, Sakamoto, Tamotsu, Salacata, Abraham, Salem, Adrien, Bodes, Rafael Salguero, Saltzman, Marco A., Salvioni, Alessandro, Vallejo, Gregorio Sanchez, Fernández, Marcelo Sanmartín, Saporito, Wladmir Faustino, Sarikonda, Kesari, Sasaoka, Taishi, Sati, Hamdi, Savelieva, Irina, Scala, Pierre-Jean, Schellinger, Peter, Scherr, Carlos, Schmitz, Lisa, Schmitz, Karl-Heinz, Schmitz, Bettina, Schnabel, Teresa, Schnupp, Steffen, Schoeniger, Peter, Schön, Norbert, Schwimmbeck, Peter, Seamark, Clare, Searles, Greg, Seidl, Karl-Heinz, Seidman, Barry, Sek, Jaroslaw, Sekaran, Lakshmanan, Serrati, Carlo, Shah, Neerav, Shah, Vinay, Shah, Anil, Shah, Shujahat, Sharma, Vijay Kumar, Shaw, Louise, Sheikh, Khalid H., Shimizu, Naruhito, Shimomura, Hideki, Shin, Dong-Gu, Shin, Eun-Seok, Shite, Junya, Sibilio, Gerolamo, Silver, Frank, Sime, Iveta, Simmers, Tim A., Singh, Narendra, Siostrzonek, Peter, Smadja, Didier, Smith, David W., Snitman, Marcelo, Filho, Dario Sobral, Soda, Hassan, Sofley, Carl, Sokal, Adam, Oi Yan, Yannie Soo, Sotolongo, Rodolfo, Ferreira de Souza, Olga, Sparby, Jon Arne, Spinar, Jindrich, Sprigings, David, Spyropoulos, Alex C., Stakos, Dimitrios, Steinwender, Clemens, Stergiou, Georgios, Stiell, Ian, Stoddard, Marcus, Stoikov, Anastas, Streb, Witold, Styliadis, Ioannis, Su, Guohai, Su, Xi, Sudnik, Wanda, Sukles, Kai, Sun, Xiaofei, Swart, H., Szavits-Nossan, Janko, Taggeselle, Jens, Takagi, Yuichiro, Singh Takhar, Amrit Pal, Tamm, Angelika, Tanaka, Katsumi, Tanawuttiwat, Tanyanan, Tang, Sherman, Tang, Aylmer, Tarsi, Giovanni, Tassinari, Tiziana, Tayal, Ashis, Tayebjee, Muzahir, Berg, J.M. ten, Tesloianu, Dan, The, Salem H.K., Thomas, Dierk, Timsit, Serge, Tobaru, Tetsuya, Tomasik, Andrzej R., Torosoff, Mikhail, Touze, Emmanuel, Trendafilova, Elina, Tsai, W. Kevin, Tse, Hung Fat, Tsutsui, Hiroshi, Tu, Tian Ming, Tuininga, Ype, Turakhia, Minang, Turk, Samir, Turner, Wayne, Tveit, Arnljot, Tytus, Richard, Valadão, C., van Bergen, P.F.M.M., van de Borne, Philippe, van den Berg, B.J., van der Zwaan, C., Van Eck, M., Vanacker, Peter, Vasilev, Dimo, Vasilikos, Vasileios, Vasilyev, Maxim, Veerareddy, Srikar, Miño; Asok Venkataraman, Mario Vega, Verdecchia, Paolo, Versaci, Francesco, Vester, Ernst Günter, Vial, Hubert, Victory, Jason, Villamil, Alejandro, Vincent, Marc, Vlastaris, Anthony, Dahl, Jürgen vom, Vora, Kishor, Vranian, Robert B., Wakefield, Paul, Wang, Ningfu, Wang, Mingsheng, Wang, Xinhua, Wang, Feng, Wang, Tian, Warner, Alberta L., Watanabe, Kouki, Wei, Jeanne, Weimar, Christian, Weiner, Stanislav, Weinrich, Renate, Wen, Ming-Shien, Wiemer, Marcus, Wiggers, Preben, Wilke, Andreas, Williams, David, Williams, Marcus L., Witzenbichler, Bernhard, Wong, Brian, Lawrence Wong, Ka Sing, Wozakowska-Kaplon, Beata, Wu, Shulin, Wu, Richard C., Wunderlich, Silke, Wyatt, Nell, Wylie, John (Jack), Xu, Yong, Xu, Xiangdong, Yamanoue, Hiroki, Yamashita, Takeshi, Bryan Yan, Ping Yen, Yang, Tianlun, Yao, Jing, Yeh, Kuo-Ho, Yin, Wei Hsian, Yotov, Yoto, Zahn, Ralf, Zarich, Stuart, Zenin, Sergei, Zeuthen, Elisabeth Louise, Zhang, Huanyi, Zhang, Donghui, Zhang, Xingwei, Zhang, Ping, Zhang, Jun, Zhao, Shui Ping, Zhao, Yujie, Zhao, Zhichen, Zheng, Yang, Zhou, Jing, Zimmermann, Sergio, Zini, Andrea, Zizzo, Steven, Zong, Wenxia, Zukerman, L. Steven, Romiti, Giulio Francesco, Corica, Bernadette, Proietti, Marco, Mei, Davide Antonio, Frydenlund, Juliane, Bisson, Arnaud, Olshansky, Brian, Chan, Yi-Hsin, Huisman, Menno V., and Chao, Tze-Fan

Published
2023
Full Text
View/download PDF

4. Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk.

Author

Rossing, Peter, Hansen, Tine Willum, and Kümler, Thomas

Subjects
DIABETIC nephropathies, MINERALOCORTICOID receptors, DISEASE risk factors, CHRONIC kidney failure, CARDIOVASCULAR diseases, NEPRILYSIN
Abstract

Chronic kidney disease (CKD) currently affects approximately 850 million people globally and is continuing to increase in prevalence as well as in importance as a cause of death. The excess mortality related to CKD is mostly caused by an increase in cardiovascular disease. This includes atherosclerotic cardiovascular disease as many promoters of atherosclerosis, such as blood pressure, lipid levels and hypercoagulation, are increased in people with CKD. Diabetes is a leading cause of CKD contributing to the risk of CVD, and obesity is also increasingly prevalent. Management of these risk factors is therefore very important in CKD, and to reduce risk of CKD progression. Heart failure is also more prevalent in CKD and, again, many risk factors are shared. The concept of foundational pillars in the management of heart failure has been adapted to the treatment of CKD, with many organ‐protective interventions, such renin‐angiotensin system blockade, sodium‐glucose cotransporter‐2 inhibition and mineralocorticoid receptor antagonism, reducing the risk for mortality in heart failure with reduced ejection fraction, but also for progression of CKD. Atrial fibrillation is also more common with CKD and affects the management of the former. In this review these non‐renal complications of CKD are discussed, along with how the risk of these complications should be managed. Many new opportunities have demonstrated heart and kidney organ protection, but implementation is a challenge. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. High risk of rehospitalization within 1 year following a pulmonary embolism-insights from the Danish nationwide registries from 2000-2020

Author

Sindet-Pedersen, Caroline, El-Chouli, Mohamad, Nouhravesh, Nina, Lamberts, Morten, Christensen, Daniel Mølager, Kümler, Thomas, Lock, Morten, Grove, Erik Lerkevang, Holt, Anders, Schou, Morten, Gislason, Gunnar, Butt, Jawad Haider, Strange, Jarl Emanuel, Sindet-Pedersen, Caroline, El-Chouli, Mohamad, Nouhravesh, Nina, Lamberts, Morten, Christensen, Daniel Mølager, Kümler, Thomas, Lock, Morten, Grove, Erik Lerkevang, Holt, Anders, Schou, Morten, Gislason, Gunnar, Butt, Jawad Haider, and Strange, Jarl Emanuel

Abstract

Aim To identify the absolute risk, causes, and factors associated with rehospitalization within 1 year of discharge with a pulmonary embolism (PE). Methods and results Using the Danish nationwide registries, all patients admitted with a first-time PE between 2000 and 2020 and discharged alive were included. Subsequent hospitalizations were categorized and crude cumulative incidences were used to estimate the absolute risk (AR) of any rehospitalization and specific causes of rehospitalizations. Risk factors for rehospitalization were investigated using cause specific Cox regression models. A total of 55 201 patients were identified. The median age of the study population was 70 years (inter quartile range: 59;79), and the most prevalent comorbidities were cancer (29.3%) and ischemic heart disease (12.7%). The 1-year AR of any rehospitalization after discharge with a PE was 48.6% (95% confidence interval (CI); 48.2%–48.8%). The most common cause for being rehospitalized was due to respiratory disease [1-year AR: 9.5% (95% CI: 9.3%–9.8%)], followed by cardiovascular disease [1-year AR: 6.3% (95% CI: 5.9%–6.5%)], cancer [1-year AR: 6.0% (95% CI: 5.8%–6.4%)], venous thromboembolism [1-year AR: 5.2% (95% CI: 5.0%–5.2%)], and symptom diagnoses [1-year AR: 5.2% (95% CI: 5.0%–5.4%)]. Factors that were associated with an increased risk of rehospitalization were cancer, liver disease, chronic obstructive pulmonary disease, chronic kidney disease, and immobilization. Conclusion Patients with PE have a high risk of rehospitalization, with almost half of patients being rehospitalized within 1 year. Identification of high-risk patients may help target interventions aiming at reducing the risk of rehospitalization., Aim: To identify the absolute risk, causes, and factors associated with rehospitalization within 1 year of discharge with a pulmonary embolism (PE). Methods and results: Using the Danish nationwide registries, all patients admitted with a first-Time PE between 2000 and 2020 and discharged alive were included. Subsequent hospitalizations were categorized and crude cumulative incidences were used to estimate the absolute risk (AR) of any rehospitalization and specific causes of rehospitalizations. Risk factors for rehospitalization were investigated using cause specific Cox regression models. A total of 55 201 patients were identified. The median age of the study population was 70 years (inter quartile range: 59;79), and the most prevalent comorbidities were cancer (29.3%) and ischemic heart disease (12.7%). The 1-year AR of any rehospitalization after discharge with a PE was 48.6% (95% confidence interval (CI); 48.2%-48.8%). The most common cause for being rehospitalized was due to respiratory disease [1-year AR: 9.5% (95% CI: 9.3%-9.8%)], followed by cardiovascular disease [1-year AR: 6.3% (95% CI: 5.9%-6.5%)], cancer [1-year AR: 6.0% (95% CI: 5.8%-6.4%)], venous thromboembolism [1-year AR: 5.2% (95% CI: 5.0%-5.2%)], and symptom diagnoses [1-year AR: 5.2% (95% CI: 5.0%-5.4%)]. Factors that were associated with an increased risk of rehospitalization were cancer, liver disease, chronic obstructive pulmonary disease, chronic kidney disease, and immobilization. Conclusion: Patients with PE have a high risk of rehospitalization, with almost half of patients being rehospitalized within 1 year. Identification of high-risk patients may help target interventions aiming at reducing the risk of rehospitalization.

Published
2024

9. High risk of rehospitalization within 1 year following a pulmonary embolism—insights from the Danish nationwide registries from 2000–2020

Author

Sindet-Pedersen, Caroline, primary, El-Chouli, Mohamad, additional, Nouhravesh, Nina, additional, Lamberts, Morten, additional, Christensen, Daniel Mølager, additional, Kümler, Thomas, additional, Lock, Morten, additional, Grove, Erik Lerkevang, additional, Holt, Anders, additional, Schou, Morten, additional, Gislason, Gunnar, additional, Butt, Jawad Haider, additional, and Strange, Jarl Emanuel, additional

Published
2023
Full Text
View/download PDF

10. Short- and Long-Term Mortality for Patients With and Without a Cancer Diagnosis Following Pulmonary Embolism in Denmark, 2000 to 2020:A Nationwide Study

Author

Madsen, Sophie Fredslund, Christensen, Daniel Mølager, Strange, Jarl Emanuel, Nouhravesh, Nina, Kümler, Thomas, Gislason, Gunnar, Lamberts, Morten, Sindet-Pedersen, Caroline, Madsen, Sophie Fredslund, Christensen, Daniel Mølager, Strange, Jarl Emanuel, Nouhravesh, Nina, Kümler, Thomas, Gislason, Gunnar, Lamberts, Morten, and Sindet-Pedersen, Caroline

Abstract

Background New treatment regimens have been introduced in the past 20 years, which may influence the short‐ and long‐term prognosis for patients with and without a cancer diagnosis following pulmonary embolism. However, newer studies investigating these trends are lacking. Therefore, we aimed to investigate the 30‐ and 31‐ to 365‐day mortality following pulmonary embolism. Methods and Results Using the Danish nationwide registries, patients with a diagnosis of pulmonary embolism between 2000 and 2020 were included. Age‐ and sex‐standardized 30‐ and 31‐ to 365‐day mortality was calculated and stratified by cancer status. In total, 60 614 patients (29.6% with recent cancer; mean age, 68.2 years) were included. The 30‐day mortality for patients with no recent cancer decreased from 19.1% (95% CI, 17.9%–20.4%) in 2000 to 7.3% (95% CI, 6.7%–8.0%) in 2018 to 2020 (hazard ratio [HR], 0.36 [95% CI, 0.32–0.40]; P<0.001). The 30‐day mortality for patients with recent cancer decreased from 32.2% (95% CI, 28.8%–36.6%) to 14.1% (95% CI, 12.7%–15.5%) (HR, 0.38 [95% CI, 0.33–0.44]; P<0.001). The 31‐ to 365‐day mortality for patients with no recent cancer decreased from 12.5% (95% CI, 11.4%–13.6%) to 9.4% (95% CI, 8.6%–10.2%) (HR, 0.73 [95% CI, 0.64–0.83]; P<0.001).The 31‐ to 365‐day mortality for patients with recent cancer remained stable: 39.4% (95% CI, 35.1%–43.7%) to 38.3% (95% CI, 35.9%–40.6%) (HR, 0.97 [95% CI, 0.84–1.12]; P=0.69). Conclusions From 2000 to 2020, improvements were observed in 30‐day mortality following pulmonary embolism regardless of cancer status. For patients with recent cancer, 31‐ to 365‐day mortality did not improve, whereas a minor improvement was observed for patients without recent cancer., BACKGROUND: New treatment regimens have been introduced in the past 20 years, which may influence the short-and long-term prognosis for patients with and without a cancer diagnosis following pulmonary embolism. However, newer studies investigating these trends are lacking. Therefore, we aimed to investigate the 30-and 31-to 365-day mortality following pulmonary embolism. METHODS AND RESULTS: Using the Danish nationwide registries, patients with a diagnosis of pulmonary embolism between 2000 and 2020 were included. Age-and sex-standardized 30-and 31-to 365-day mortality was calculated and stratified by cancer status. In total, 60 614 patients (29.6% with recent cancer; mean age, 68.2 years) were included. The 30-day mortality for patients with no recent cancer decreased from 19.1% (95% CI, 17.9%–20.4%) in 2000 to 7.3% (95% CI, 6.7%–8.0%) in 2018 to 2020 (hazard ratio [HR], 0.36 [95% CI, 0.32–0.40]; P<0.001). The 30-day mortality for patients with recent cancer decreased from 32.2% (95% CI, 28.8%–36.6%) to 14.1% (95% CI, 12.7%–15.5%) (HR, 0.38 [95% CI, 0.33–0.44]; P<0.001). The 31-to 365-day mortality for patients with no recent cancer decreased from 12.5% (95% CI, 11.4%–13.6%) to 9.4% (95% CI, 8.6%–10.2%) (HR, 0.73 [95% CI, 0.64–0.83]; P<0.001).The 31-to 365-day mortality for patients with recent cancer remained stable: 39.4% (95% CI, 35.1%–43.7%) to 38.3% (95% CI, 35.9%–40.6%) (HR, 0.97 [95% CI, 0.84–1.12]; P=0.69). CONCLUSIONS: From 2000 to 2020, improvements were observed in 30-day mortality following pulmonary embolism regard-less of cancer status. For patients with recent cancer, 31-to 365-day mortality did not improve, whereas a minor improvement was observed for patients without recent cancer.

Published
2023

12. 'No one told me anything about it and I cannot explain it':Illness perception in symptomatic and asymptomatic patients with cancer-associated thrombosis

Author

Nouhravesh, Nina, Sindet-Pedersen, Caroline, Kümler, Thomas, Schou, Morten, Lamberts, Morten K, and Højen, Anette Arbjerg

Subjects
Cardio-oncology, Neoplasms, cancer-associated thrombosis, Pulmonary embolism, cancer, Humans, Patient Compliance, Thrombosis, Neoplasms/complications, Perception, Hematology, Thrombosis/etiology
Abstract

INTRODUCTION: Patients with cancer, have reported cancer-associated thrombosis (CAT), a distressing event in their overall illness. However, whether the clinical presentation of CAT; symptomatic versus asymptomatic, impacts illness perception is poorly elucidated. The aim of this study was to explore illness perception in patients with CAT, stratified by the clinical presentation.MATERIALS AND METHODS: In a qualitative design, we conducted a three-step workshop. Patients were included from a specialised cardiology care unit for oncology patients. Data analysis was performed using framework analysis. The analytic framework was based on the five components of illness perception: (1) identity of illness, (2) causal beliefs, (3) timeline beliefs, (4) beliefs about control/cure and (5) consequences.RESULTS: Elleven patients with CAT participated in the workshop; five symptomatic and six asymptomatic. Whitin each category of illness perception following notions emerged (1) the identity of CAT was only tangible for symptomatic participants, (2) the aetiology was considered important information for symptomatic participants, which was in contrast to asymptomatic participants, (3) asymptomatic participant did not consider recurrent CAT a threat towards their health, (4) asymptomatic participants were prone to information overload, whilst information was imperative to the sense of control in symptomatic participants, (5) low molecular weight heparin treatment was accepted in symptomatic participants due to remission of symptoms.CONCLUSIONS: The clinical presentation of CAT (asymptomatic/symptomatic) proved essential to illness perception. These findings indicate that information level and communication within the medical consultation, should actively consider the clinical presentation of CAT in order to optimize management and compliance.

Published
2022

15. Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (Clinical Research in Cardiology, (2022), 111, 5, (560-573), 10.1007/s00392-022-01996-2)

Author

Lip, Gregory Y. H., Kotalczyk, Agnieszka, Teutsch, Christine, Diener, Hans-Christoph, Dubner, Sergio J., Halperin, Jonathan L., Ma, Chang-Sheng, Rothman, Kenneth J., Marler, Sabrina, Gurusamy, Venkatesh Kumar, Huisman, Menno V., Abban, Dzifa Wosornu, Aziz, Emad, Kalan, Marica Bracic, Abdul, Nasser, Backes, Luciano Marcelo, Bradman, Drew, Abud, Atilio Marcelo, Badings, E., Brautigam, Donald, Adams, Fran, Bagni, Ermentina, Breton, Nicolas, Addala, Srinivas, Baker, Seth H., Brouwers, P. J. A. M., Adragão, Pedro, Bala, Richard, Browne, Kevin, Ageno, Walter, Baldi, Antonio, Cortada, Jordi Bruguera, Aggarwal, Rajesh, Bando, Shigenobu, Bruni, A., Agosti, Sergio, Banerjee, Subhash, Brunschwig, Claude, Agostoni, Piergiuseppe, Bank, Alan, Buathier, Hervé, Aguilar, Francisco, Esquivias, Gonzalo Barón, Buhl, Aurélie, Linares, Julio Aguilar, Barr, Craig, Bullinga, John, Aguinaga, Luis, Bartlett, Maria, Cabrera, Jose Walter, Ahmed, Jameel, Basic Kes, Vanja, Caccavo, Alberto, Aiello, Allessandro, Baula, Giovanni, Cai, Shanglang, Ainsworth, Paul, Behrens, Steffen, Caine, Sarah, Aiub, Jorge Roberto, Bell, Alan, Calò, Leonardo, Al-Dallow, Raed, Benedetti, Raffaella, Calvi, Valeria, Alderson, Lisa, Mazuecos, Juan Benezet, Sánchez, Mauricio Camarillo, Velasco, Jorge Antonio Aldrete, Benhalima, Bouziane, Candeias, Rui, Alexopoulos, Dimitrios, Bergler-Klein, Jutta, Capuano, Vincenzo, Manterola, Fernando Alfonso, Berneau, Jean-Baptiste, Capucci, Alessandro, Aliyar, Pareed, Bernstein, Richard A., Caputo, Ronald, Alonso, David, Berrospi, Percy, Rizo, Tatiana C. rdenas, da Costa, Fernando Augusto Alves, Berti, Sergio, Cardona, Francisco, Amado, José, Berz, Andrea, da Costa Darrieux, Francisco Carlos, Amara, Walid, Best, Elizabeth, Vera, Yan Carlos Duarte, Amelot, Mathieu, Bettencourt, Paulo, Carolei, Antonio, Amjadi, Nima, Betzu, Robert, Carreño, Susana, Ammirati, Fabrizio, Bhagwat, Ravi, Carvalho, Paula, Andrade, Marianna, Bhatta, Luna, Cary, Susanna, Andrawis, Nabil, Biscione, Francesco, Casu, Gavino, Annoni, Giorgio, Bisignani, Giovanni, Cavallini, Claudio, Ansalone, Gerardo, Black, Toby, Cayla, Guillaume, Ariani, M. Kevin, Bloch, Michael J., Celentano, Aldo, Arias, Juan Carlos, Bloom, Stephen, Cha, Tae-Joon, Armero, S. bastien, Blumberg, Edwin, Cha, Kwang Soo, Arora, Chander, Bo, Mario, Chae, Jei Keon, Aslam, Muhammad Shakil, Bøhmer, Ellen, Chalamidas, Kathrine, Asselman, M., Bollmann, Andreas, Challappa, Krishnan, Audouin, Philippe, Bongiorni, Maria Grazia, Chand, Sunil Prakash, Augenbraun, Charles, Boriani, Giuseppe, Chandrashekar, Harinath, Aydin, S., Boswijk, D. J., Chartier, Ludovic, Bott, Jochen, Chatterjee, Kausik, Ayryanova, Ivaneta, Bottacchi, Edo, Ayala, Carlos Antero Chavez, Cheema, Aamir, Davis, Gershan, Evonich, Rudolph, Cheema, Amjad, Davy, Jean-Marc, Evseeva, Oksana, Chen, Lin, Dayer, Mark, Ezhov, Andrey, Chen, Shih-Ann, de Biasio, Marzia, Fahmy, Raed, Chen, Jyh Hong, de Bonis, Silvana, Fang, Quan, Chiang, Fu-Tien, de Caterina, Raffaele, Farsad, Ramin, Chiarella, Francesco, de Franceschi, Teresiano, Fauchier, Laurent, Chih-Chan, Lin, de Groot, J. R., Favale, Stefano, Cho, Yong Keun, de Horta, José, Fayard, Maxime, Choi, Jong-Il, de la Briolle, Axel, Fedele, Jose Luis, Choi, Dong Ju, de la Pena Topete, Gilberto, Fedele, Francesco, Chouinard, Guy, de Paola, Angelo Amato Vicenzo, Fedorishina, Olga, Chow, Danny Hoi-Fan, de Souza, Weimar, Fera, Steven R., Chrysos, Dimitrios, de Veer, A., Ferreira, Luis Gustavo Gomes, Chumakova, Galina, de Wolf, Luc, Ferreira, Jorge, Valenzuela, Eduardo Julián José Roberto Chuquiure, Decoulx, Eric, Ferri, Claudio, Nica, Nicoleta Cindea, Deepak, Sasalu, Ferrier, Anna, Cislowski, David J., Defaye, Pascal, Ferro, Hugo, Clay, Anthony, Munoz, Freddy Del-Carpio, Finsen, Alexandra, Clifford, Piers, Brkljacic, Diana Delic, First, Brian, Cohen, Andrew, Deumite, N. Joseph, Fischer, Stuart, Cohen, Michael, di Legge, Silvia, Fonseca, Catarina, Cohen, Serge, Diemberger, Igor, Almeida, Luísa Fonseca, Colivicchi, Furio, Dietz, Denise, Forman, Steven, Collins, Ronan, Dionísio, Pedro, Frandsen, Brad, Colonna, Paolo, Dong, Qiang, French, William, Compton, Steve, dos Santos, Fabio Rossi, Friedman, Keith, Connolly, Derek, Dotcheva, Elena, Friese, Athena, Conti, Alberto, Doukky, Rami, Fruntelata, Ana Gabriela, Buenostro, Gabriel Contreras, D’Souza, Anthony, Fujii, Shigeru, Coodley, Gregg, Dubrey, Simon, Fumagalli, Stefano, Cooper, Martin, Ducrocq, Xavier, Fundamenski, Marta, Coronel, Julian, Dupljakov, Dmitry, Furukawa, Yutaka, Corso, Giovanni, Duque, Mauricio, Gabelmann, Matthias, Sales, Juan Cosín, Dutta, Dipankar, Gabra, Nashwa, Cottin, Yves, Duvilla, Nathalie, Gadsbøll, Niels, Covalesky, John, Duygun, A., Galinier, Michel, Cracan, Aurel, Dziewas, Rainer, Gammelgaard, Anders, Crea, Filippo, Eaton, Charles B., Ganeshkumar, Priya, Crean, Peter, Eaves, William, Gans, Christopher, Crenshaw, James, Ebels-Tuinbeek, L. A., Quintana, Antonio Garcia, Cullen, Tina, Ehrlich, Clifford, Gartenlaub, Olivier, Darius, Harald, Eichinger-Hasenauer, Sabine, Gaspardone, Achille, Dary, Patrick, Eisenberg, Steven J., Genz, Conrad, Dascotte, Olivier, Jabali, Adnan El, Georger, Frédéric, Dauber, Ira, Shahawy, Mahfouz El, Georges, Jean-Louis, Davalos, Vicente, Hernandes, Mauro Esteves, Georgeson, Steven, Davies, Ruth, Izal, Ana Etxeberria, Giedrimas, Evaldas, Gierba, Mariusz, Haruna, Tetsuya, Jarmukli, Nabil, Ortega, Ignacio Gil, Hayek, Emil, Jeanfreau, Robert J., Gillespie, Eve, Healey, Jeff, Jenkins, Ronald D., Giniger, Alberto, Hearne, Steven, Sánchez, Carlos Jerjes, Giudici, Michael C., Heffernan, Michael, Jimenez, Javier, Gkotsis, Alexandros, Heggelund, Geir, Jobe, Robert, Glotzer, Taya V., Heijmeriks, J. A., Joen-Jakobsen, Tomas, Gmehling, Joachim, Hemels, Maarten, Jones, Nicholas, Gniot, Jacek, Hendriks, I., Jorge, Jose Carlos Moura, Goethals, Peter, Henein, Sam, Jouve, Bernard, Goldbarg, Seth, Her, Sung-Ho, Jung, Byung Chun, Goldberg, Ronald, Hermany, Paul, Jung, Kyung Tae, Goldmann, Britta, del Río, Jorge Eduardo Hernández, Jung, Werner, Golitsyn, Sergey, Higashino, Yorihiko, Kachkovskiy, Mikhail, Gómez, Silvia, Hill, Michael, Kafkala, Krystallenia, Mesa, Juan Gomez, Hisadome, Tetsuo, Kalinina, Larisa, Gonzalez, Vicente Bertomeu, Hishida, Eiji, Kallmünzer, Bernd, Hermosillo, Jesus Antonio Gonzalez, Hoffer, Etienne, Kamali, Farzan, López, V. ctor Manuel González, Hoghton, Matthew, Kamo, Takehiro, Gorka, Hervé, Hong, Kui, Kampus, Priit, Gornick, Charles, Hong, Suk keun, Kashou, Hisham, Gorog, Diana, Horbach, Stevie, Kastrup, Andreas, Gottipaty, Venkat, Horiuchi, Masataka, Katsivas, Apostolos, Goube, Pascal, Hou, Yinglong, Kaufman, Elizabeth, Goudevenos, Ioannis, Hsing, Jeff, Kawai, Kazuya, Graham, Brett, Huang, Chi-Hung, Kawajiri, Kenji, Greer, G. Stephen, Huckins, David, Kazmierski, John F., Gremmler, Uwe, Hughes, Kathy, Keeling, P., Grena, Paul G., Huizinga, A., Saraiva, José Francisco Kerr, Grond, Martin, Hulsman, E. L., Ketova, Galina, Gronda, Edoardo, Hung, Kuo-Chun, Khaira, Ajit Singh, Grönefeld, Gerian, Hwang, Gyo-Seung, Khripun, Aleksey, Gu, Xiang, Ikpoh, Margaret, Kim, Doo-Il, Torres, Ivett Guadalupe Torres, Imberti, Davide, Kim, Young Hoon, Guardigli, Gabriele, Ince, H. seyin, Kim, Nam Ho, Guevara, Carolina, Indolfi, Ciro, Kim, Dae Kyeong, Guignier, Alexandre, Inoue, Shujiro, Kim, Jeong Su, Gulizia, Michele, Irles, Didier, Kim, June Soo, Gumbley, Michael, Iseki, Harukazu, Kim, Ki Seok, Günther, Albrecht, Israel, C. Noah, Kim, Jin bae, Ha, Andrew, Iteld, Bruce, Kinova, Elena, Hahalis, Georgios, Iyer, Venkat, Klein, Alexander, Hakas, Joseph, Jackson-Voyzey, Ewart, Kmetzo, James J., Hall, Christian, Jaffrani, Naseem, Kneller, G. Larsen, Han, Bing, Jäger, Frank, Knezevic, Aleksandar, Han, Seongwook, James, Martin, Koh, Su Mei Angela, Hargrove, Joe, Jang, Sung-Won, Koide, Shunichi, Hargroves, David, Jaramillo, Nicolas, Kollias, Anastasios, Kooistra, J. A., Li, Weihua, McClure, John, Koons, Jay, Li, Xiaoming, McCormack, Terry, Koschutnik, Martin, Lichy, Christhoh, McGarity, William, Kostis, William J., Lieber, Ira, McIntyre, Hugh, Kovacic, Dragan, Rodriguez, Ramon Horacio Limon, McLaurin, Brent, Kowalczyk, Jacek, Lin, Hailong, Alvaro, Feliz, Palomino, Medina, Koziolova, Natalya, Melandri, Francesco, Kraft, Peter, Liu, Feng, Meno, Hiroshi, Kragten, Johannes A., Liu, Hengliang, Menzies, Dhananjai, Krantz, Mori, Esperon, Guillermo Llamas, Mercader, Marco, Krause, Lars, Navarro, Nassip Llerena, Meyer, Christian, Krenning, B. J., Lo, Eric, Meyer, Beat J., Krikke, F., Lokshyn, Sergiy, Miarka, Jacek, Kromhout, Z., López, Amador, Mibach, Frank, Krysiak, Waldemar, López-Sendón, José Luís, Michalski, Dominik, Kumar, Priya, Filho, Adalberto Menezes Lorga, Michel, Patrik, Kümler, Thomas, Lorraine, Richard S., Chreih, Rami Mihail, Kuniss, Malte, Luengas, Carlos Alberto, Luengas, Alberto, Mikdadi, Ghiath, Kuo, Jen-Yuan, Luke, Robert, Mikus, Milan, Küppers, Achim, Luo, Ming, Milicic, Davor, Kurrelmeyer, Karla, Lupovitch, Steven, Militaru, Constantin, Kwak, Choong Hwan, Lyrer, Philippe, Minaie, Sedi, Laboulle, B. nédicte, Ma, Changsheng, Minescu, Bogdan, Labovitz, Arthur, Ma, Genshan, Mintale, Iveta, ter Lai, Wen, Madariaga, Irene, Mirault, Tristan, Lam, Andy, Maeno, Koji, Mirro, Michael J., Lam, Yat Yin, Magnin, Dominique, Mistry, Dinesh, Lanas Zanetti, Fernando, Maid, Gustavo, Miu, Nicoleta Violeta, Landau, Charles, Mainigi, Sumeet K., Miyamoto, Naomasa, Landini, Giancarlo, Makaritsis, Konstantinos, Moccetti, Tiziano, Lanna Figueiredo, Estêvão, Malhotra, Rohit, Mohammed, Akber, Larsen, Torben, Manning, Rickey, Nor, Azlisham Mohd, Lavandier, Karine, Manolis, Athanasios, Mollerus, Michael, LeBlanc, Jessica, Hurtado, Helard Andres Manrique, Molon, Giulio, Lee, Moon Hyoung, Mantas, Ioannis, Mondillo, Sergio, Lee, Chang-Hoon, Jattin, Fernando Manzur, Moniz, Patrícia, Lehman, John, Maqueda, Vicky, Mont, Lluis, Leitão, Ana, Marchionni, Niccolo, Montagud, Vicente, Lellouche, Nicolas, Ortuno, Francisco Marin, Montaña, Oscar, Lelonek, Malgorzata, Santana, Antonio Martín, Monti, Cristina, Lenarczyk, Radoslaw, Martinez, Jorge, Moretti, Luciano, Lenderink, T., Maskova, Petra, Mori, Kiyoo, González, Salvador León, Hernandez, Norberto Matadamas, Moriarty, Andrew, Leong-Sit, Peter, Matsuda, Katsuhiro, Morka, Jacek, Leschke, Matthias, Maurer, Tillmann, Moschini, Luigi, Ley, Nicolas, Mauro, Ciro, Moschos, Nikitas, Li, Zhanquan, May, Erik, Mügge, Andreas, Li, Xiaodong, Mayer, Nolan, Mulhearn, Thomas J., Muresan, Carmen, Jose, Eena Padayattil, Précoma, Dalton Bertolim, Muriago, Michela, Padilla, Francisco Gerardo Padilla, Prelle, Alessandro, Musial, Wlodzimierz, Rios, Victoria Padilla, Prodafikas, John, Musser, Carl W., Pajes, Giuseppe, Protasov, Konstantin, Musumeci, Francesco, Pandey, A. Shekhar, Pye, Maurice, Nageh, Thuraia, Paparella, Gaetano, Qiu, Zhaohui, Nakagawa, Hidemitsu, Paris, F., Quedillac, Jean-Michel, Nakamura, Yuichiro, Park, Hyung Wook, Raev, Dimitar, Nakayama, Toru, Park, Jong Sung, Grado, Carlos Antonio Raffo, Nam, Gi-Byoung, Parthenakis, Fragkiskos, Rahimi, Sidiqullah, Nanna, Michele, Passamonti, Enrico, Raisaro, Arturo, Natarajan, Indira, Patel, Rajesh J., Rama, Bhola, Nayak, Hemal M., Patel, Jaydutt, Ramos, Ricardo, Naydenov, Stefan, Patel, Mehool, Ranieri, Maria, Nazlić, Jurica, Patrick, Janice, Raposo, Nuno, Nechita, Alexandru Cristian, Jimenez, Ricardo Pavón, Rashba, Eric, Nechvatal, Libor, Paz, Analía, Rauch-Kroehnert, Ursula, Negron, Sandra Adela, Pengo, Vittorio, Reddy, Ramakota, Neiman, James, Pentz, William, Renda, Giulia, Neuenschwander, Fernando Carvalho, Pérez, Beatriz, Reza, Shabbir, Neves, David, Ríos, Alma Minerva P. rez, Ria, Luigi, Neykova, Anna, Pérez-Cabezas, Alejandro, Richter, Dimitrios, Miguel, Ricardo Nicolás, Perlman, Richard, Rickli, Hans, Nijmeh, George, Persic, Viktor, Rieker, Werner, Nizov, Alexey, Perticone, Francesco, Vera, Tomas Ripolil, Campos, Rodrigo Noronha, Peters, Terri K., Ritt, Luiz Eduardo, Nossan, Janko, Petkar, Sanjiv, Roberts, Douglas, Novikova, Tatiana, Pezo, Luis Felipe, Briones, Ignacio Rodriguez, Nowalany-Kozielska, Ewa, Pflücke, Christian, Escudero, Aldo Edwin Rodriguez, Nsah, Emmanuel, Pham, David N., Pascual, Carlos Rodríguez, Fragoso, Juan Carlos Nunez, Phillips, Roland T., Roman, Mark, Nurgalieva, Svetlana, Phlaum, Stephen, Romeo, Francesco, Nuyens, Dieter, Pieters, Denis, Ronner, E., Nyvad, Ole, Pineau, Julien, Roux, Jean-Francois, de Los Rios Ibarra, Manuel Odin, Pinter, Arnold, Rozkova, Nadezda, O’Donnell, Philip, Pinto, Fausto, Rubacek, Miroslav, O’Donnell, Martin, Pisters, R., Rubalcava, Frank, Oh, Seil, Pivac, Nediljko, Russo, Andrea M., Oh, Yong Seog, Pocanic, Darko, Rutgers, Matthieu Pierre, Oh, Dongjin, Podoleanu, Cristian, Rybak, Karin, O‘Hara, Gilles, Politano, Alessandro, Said, Samir, Oikonomou, Kostas, Poljakovic, Zdravka, Sakamoto, Tamotsu, Olivares, Claudia, Pollock, Stewart, Salacata, Abraham, Oliver, Richard, Garcéa, Jose Polo, Salem, Adrien, Ruiz, Rafael Olvera, Poppert, Holger, Bodes, Rafael Salguero, Olympios, Christoforos, Porcu, Maurizio, Saltzman, Marco A., Omaszuk-Kazberuk, Anna, Reino, Antonio Pose, Salvioni, Alessandro, Asensi, Joaquín Osca, Prasad, Neeraj, Vallejo, Gregorio Sanchez, Fernández, Marcelo Sanmartín, Sokal, Adam, Tu, Tian Ming, Saporito, Wladmir Faustino, Yan, Yannie Soo Oi, Tuininga, Ype, Sarikonda, Kesari, Sotolongo, Rodolfo, Turakhia, Minang, Sasaoka, Taishi, de Souza, Olga Ferreira, Turk, Samir, Sati, Hamdi, Sparby, Jon Arne, Turner, Wayne, Savelieva, Irina, Spinar, Jindrich, Tveit, Arnljot, Scala, Pierre-Jean, Sprigings, David, Tytus, Richard, Schellinger, Peter, Spyropoulos, Alex C., Valadão, C., Scherr, Carlos, Stakos, Dimitrios, van Bergen, P. F. M. M., Schmitz, Lisa, Steinwender, Clemens, van de Borne, Philippe, Schmitz, Karl-Heinz, Stergiou, Georgios, van den Berg, B. J., Schmitz, Bettina, Stiell, Ian, van der Zwaan, C., Schnabel, Teresa, Stoddard, Marcus, van Eck, M., Schnupp, Steffen, Stoikov, Anastas, Vanacker, Peter, Schoeniger, Peter, Streb, Witold, Vasilev, Dimo, Schön, Norbert, Styliadis, Ioannis, Vasilikos, Vasileios, Schwimmbeck, Peter, Su, Guohai, Vasilyev, Maxim, Seamark, Clare, Su, Xi, Veerareddy, Srikar, Searles, Greg, Sudnik, Wanda, Miño, Mario Vega, Seidl, Karl-Heinz, Sukles, Kai, Venkataraman, Asok, Seidman, Barry, Sun, Xiaofei, Verdecchia, Paolo, Sek, Jaroslaw, Swart, H., Versaci, Francesco, Sekaran, Lakshmanan, Szavits-Nossan, Janko, Vester, Ernst G. nter, Serrati, Carlo, Taggeselle, Jens, Vial, Hubert, Shah, Neerav, Takagi, Yuichiro, Victory, Jason, Shah, Vinay, Takhar, Amrit Pal Singh, Villamil, Alejandro, Shah, Anil, Tamm, Angelika, Vincent, Marc, Shah, Shujahat, Tanaka, Katsumi, Vlastaris, Anthony, Sharma, Vijay Kumar, Tanawuttiwat, Tanyanan, Dahl, J. rgen vom, Shaw, Louise, Tang, Sherman, Vora, Kishor, Sheikh, Khalid H., Tang, Aylmer, Vranian, Robert B., Shimizu, Naruhito, Tarsi, Giovanni, Wakefield, Paul, Shimomura, Hideki, Tassinari, Tiziana, Wang, Ningfu, Shin, Dong-Gu, Tayal, Ashis, Wang, Mingsheng, Shin, Eun-Seok, Tayebjee, Muzahir, Wang, Xinhua, Shite, Junya, Berg, J. M. ten, Wang, Feng, Sibilio, Gerolamo, Tesloianu, Dan, Wang, Tian, Silver, Frank, The, Salem H. K., Warner, Alberta L., Sime, Iveta, Thomas, Dierk, Watanabe, Kouki, Simmers, Tim A., Timsit, Serge, Wei, Jeanne, Singh, Narendra, Tobaru, Tetsuya, Weimar, Christian, Siostrzonek, Peter, Tomasik, Andrzej R., Weiner, Stanislav, Smadja, Didier, Torosoff, Mikhail, Weinrich, Renate, Smith, David W., Touze, Emmanuel, Wen, Ming-Shien, Snitman, Marcelo, Trendafilova, Elina, Wiemer, Marcus, Filho, Dario Sobral, Tsai, W. Kevin, Wiggers, Preben, Soda, Hassan, Tse, Hung Fat, Wilke, Andreas, Sofley, Carl, Tsutsui, Hiroshi, Williams, David, Williams, Marcus L., Yan, Ping Yen Bryan, Zhang, Ping, Witzenbichler, Bernhard, Yang, Tianlun, Zhang, Jun, Wong, Brian, Yao, Jing, Zhao, Shui Ping, Wong, Ka Sing Lawrence, Yeh, Kuo-Ho, Zhao, Yujie, Wozakowska-Kaplon, Beata, Yin, Wei Hsian, Zhao, Zhichen, Wu, Shulin, Yotov, Yoto, Zheng, Yang, Wu, Richard C., Zahn, Ralf, Zhou, Jing, Wunderlich, Silke, Zarich, Stuart, Zimmermann, Sergio, Wyatt, Nell, Zenin, Sergei, Zini, Andrea, Wylie, John, Zeuthen, Elisabeth Louise, Zizzo, Steven, Xu, Yong, Zhang, Huanyi, Zong, Wenxia, Xu, Xiangdong, Zhang, Donghui, Zukerman, L. Steven, Yamanoue, Hiroki, Zhang, Xingwei, Yamashita, Takeshi, Cardiology, and ACS - Heart failure & arrhythmias

Abstract

In this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected.

Published
2022

16. Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin

Author

Vitfell-Rasmussen, Joanna, Krarup-Hansen, Anders, Vaage-Nilsen, Merete, Kümler, Thomas, Zerahn, Bo, Vitfell-Rasmussen, Joanna, Krarup-Hansen, Anders, Vaage-Nilsen, Merete, Kümler, Thomas, and Zerahn, Bo

Abstract

Background: Anthracycline induced cardiotoxicity is well recognized but only few data exist in sarcoma patients. This study retrospectively aimed to analyze sequential Cadmium Zinc Telluride (CZT)-multigated equilibrium radionuclide angiography (ERNA) for monitoring left ventricular ejection fraction (LVEF) and to assess the real-life incidence of cardiotoxicity in sarcoma patients receiving doxorubicin based chemotherapy. Materials and methods: A retrospective analysis was performed on all sarcoma patients referred to Herlev University Hospital between 2012 and 2015. Cardiotoxicity was defined as a decline in LVEF of > 10% percentage point to a LVEF < 50% as compared to baseline. Early cardiotoxicity was defined as < 1 year and late cardiotoxicity as ≥ 1 year. Recovery of cardiotoxicity was defined as a LVEF ≥ 50%. Results: A total of 149 patients were referred, 75 (50%) sarcoma patients were included. The main reason for exclusion was that only one CZT-ERNA had been performed in 50 (68%) of the patients. Twenty-three (31%) of the patients experienced cardiotoxicity, 11 (48%) were female, mean age was 56.9 years. Early cardiotoxicity was observed in 16 (70%) of the patients and 11 (48%) experienced clinical symptoms of cardiotoxicity at diagnosis. Recovery of LVEF was seen in 12 (55%) of the patients and persistent recovery in 10 (45%). The diastolic blood pressure at baseline was positively and significantly associated with a higher risk of developing cardiotoxicity (Relative Risk (RR): 1.039 (95% CI= 1.001 − 1.079; p = 0.042)). The median survival was 1.4 years (range 0.5 − 2.2 years) for patients with metastatic disease versus 3.9 years (range 1.5 − 6.4 years) (p = 0.009) for localized disease at baseline. Conclusion: Cardiotoxicity is a relative frequent complication in sarcoma patients treated with doxorubicin based chemotherapy and the diastolic blood pressure at baseline was significantly associated with a higher risk of developing cardiotoxicity

Published
2022

20. Venøs tromboembolisk sygdom ved COVID-19

Author

Hellfritzsch, Maja, Kümler, Thomas, Hansen, Anette Tarp, Tang, Marianne, Berthelsen, Kasper Gymoese, Fialla, Annette Dam, Andersen, Anita Sylvest, Kampmann, Peter, and Hvas, Anne-Mette

Subjects
Coronavirus, Betacoronavirus, Pneumonia, Viral, Anticoagulants, Humans, Venous Thromboembolism, Coronavirus Infections, Pulmonary Embolism, Isoflavones, Pandemics
Abstract

The importance of venous thromboembolism (VTE) as a major complication in patients with severe corona virus disease 2019 (COVID-19) is becoming increasingly evident. In this review, we describe the proposed pathophysiology of the prothrombotic coagulation changes observed in patients with COVID-19. Further, based on a review of the currently available evidence on VTE prevalence in patients with COVID-19, we present and discuss the recommendations from the Danish Society of Thrombosis and Haemostasis on the use of thromboprophylaxis in patients with COVID-19.

Published
2020

21. Akral iskæmi med multiple mikrotromber og truende gangræn ved COVID-19-infektion

Author

Andersen, Mathilde Borring, Lund, Marie Louise, Jacobsen, Søren, Kümler, Thomas, Simonsen, Stine, Ravn, Pernille, Andersen, Mathilde Borring, Lund, Marie Louise, Jacobsen, Søren, Kümler, Thomas, Simonsen, Stine, and Ravn, Pernille

Abstract

This is a report of an atypical presentation of COVID-19. The patient had sparse pulmonary symptoms despite characteristic COVID-19 lesions on CT-thorax and developed severe acral ischaemic change, after a few days of hospitalisation. The condition could not be explained by classical sepsis with hypotension and hypoperfusion, disseminated intravascular coagulation, vasculitis, endocarditis or severe peripheral arteriosclerosis. A skin biopsy showed microthrombosis, interpreted as an activation of the coagulation system associated with COVID-19. Apparently, there are multiple COVID-19 phenotypes.

Published
2020

22. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer

Author

Dyhl-Polk, Anne, Vaage-Nilsen, Merete, Schou, Morten, Vistisen, Kirsten Kjeldgaard, Lund, Cecilia Margareta, Kümler, Thomas, Appel, Jon Michael, Nielsen, Dorte Lisbet, Dyhl-Polk, Anne, Vaage-Nilsen, Merete, Schou, Morten, Vistisen, Kirsten Kjeldgaard, Lund, Cecilia Margareta, Kümler, Thomas, Appel, Jon Michael, and Nielsen, Dorte Lisbet

Abstract

Background: Fluoropyrimidines are mainstay chemotherapeutics in the treatment of gastrointestinal cancers and are also used to treat breast cancer and head and neck cancers. However, 5-flourouracil (5-FU) and capecitabine may induce cardiotoxicity that mostly presents as acute coronary syndromes. We compared the incidence of cardiotoxicity induced by 5-FU and capecitabine in patients with colorectal cancer and sought to identify risk markers for cardiotoxicity. Methods: We reviewed all consecutive patients with colorectal cancer who received 5-FU or capecitabine at one institution in the neoadjuvant (2007–2016), adjuvant (2000–2016) or metastatic setting (2007–2016). Results: Totally, 995 patients received 5-FU and 1241 received capecitabine. The incidence of cardiotoxicity induced by 5-FU was 5.2% [95% confidence interval (CI): 3.8–6.6%] and 4.1% (95% CI: 3.0–5.2%) induced by capecitabine (p =.21). The most common events were angina without ischemia (5-FU: 1.6%, capecitabine: 1.3%, p =.53), angina with ischemia on ECG (5-FU: 0.9%, capecitabine: 0.8%, p =.53), unspecified chest pain (5-FU: 0.9%, capecitabine: 0.6%, p =.34), ST-elevation myocardial infarction (5-FU: 0.5%; capecitabine: 0.4%, p =.76) and non-ST-elevation myocardial infarction (5-FU: 0.7%, capecitabine: 0.5%, p =.50). Cardiac arrest or sudden death occurred in 0.5 and 0.4%, respectively (p = 1). No risk markers for cardiotoxicity induced by 5-FU were identified. In the capecitabine group, ischemic heart disease was a risk marker (odds ratio: 2.9, 95% CI: 1.2–7.0, p =.016). Conclusions: Five percent of patients treated with 5-FU developed cardiotoxicity and 4% treated with capecitabine. Ischemic heart disease was a risk marker for cardiotoxicity induced by capecitabine.

Published
2020

23. One-year outcomes in atrial fibrillation presenting during infections:A nationwide registry-based study

Author

Gundlund, Anna, Olesen, Jonas Bjerring, Butt, Jawad H., Christensen, Mathias Aagaard, Gislason, Gunnar H., Torp-Pedersen, Christian, Køber, Lars, Kümler, Thomas, Fosbøl, Emil Loldrup, Gundlund, Anna, Olesen, Jonas Bjerring, Butt, Jawad H., Christensen, Mathias Aagaard, Gislason, Gunnar H., Torp-Pedersen, Christian, Køber, Lars, Kümler, Thomas, and Fosbøl, Emil Loldrup

Abstract

Aims: Thromboprophylaxis guidelines for patients with concurrent atrial fibrillation (AF) during infections are unclear and not supported by data. We compared 1-year outcomes in patients with infection-related AF and infection without AF. Methods and results: By crosslinking Danish nationwide registry data, AF naïve patients admitted with infection (1996-2016) were identified. Those with AF during the infection (infection-related AF) were matched 1:3 according to age, sex, type of infection, and year with patients with infection without AF. Outcomes (AF, thromboembolic events) were assessed by multivariable Cox regression. The study population comprised 30 307 patients with infection-related AF and 90 912 patients with infection without AF [median age 79 years (interquartile range 71-86), 47.6% males in both groups]. The 1-year absolute risk of AF and thromboembolic events were 36.4% and 7.6%, respectively (infection-related AF) and 1.9% and 4.4%, respectively (infection without AF). In the multivariable analyses, infection-related AF was associated with an increased long-term risk of AF and thromboembolic events compared with infection without AF: hazard ratio (HR) 25.98, 95% confidence interval (CI) 24.64-27.39 for AF and HR 2.10, 95% CI 1.98-2.22 for thromboembolic events. Further, differences in risks existed across different subtypes of infections. Conclusion: During the first year after discharge, 36% of patients with infection-related AF had a new hospital contact with AF. Infection-related AF was associated with increased risk of thromboembolic events compared with infection without AF and our results suggest that AF related to infection may merit treatment and follow-up similar to that of AF not related to infection.

Published
2020

24. Early stages of obesity-related heart failure are associated with natriuretic peptide deficiency and an overall lack of neurohormonal activation:The Copenhagen heart failure risk study

Author

Gaborit, Freja Stoltze, Kistorp, Caroline, Kümler, Thomas, Hassager, Christian, Tønder, Niels, Iversen, Kasper, Kamstru, Pia R., Faber, Jens, Køber, Lars, Schou, Morten, Gaborit, Freja Stoltze, Kistorp, Caroline, Kümler, Thomas, Hassager, Christian, Tønder, Niels, Iversen, Kasper, Kamstru, Pia R., Faber, Jens, Køber, Lars, and Schou, Morten

Abstract

Objective: This study evaluated the associations between the natriuretic peptide activity and the neurohormonal response in non-obese and obese outpatients with and without heart failure (HF). Background: Obesity-related HF may be a distinct subtype of HF. Obesity is associated with lower plasma concentrations of natriuretic peptides. The associations between obesity and neurohormonal activation estimated by mid-regional pro-adrenomedullin (MR-proADM) and copeptin in patients with HF is not elucidated. Methods: This prospective cohort-study included 392 outpatients ≥ 60years, plus ≥ 1 risk-factor(-s) for HF (hypertension, ischemic heart disease, atrial fibrillation, diabetes, chronic kidney disease), and without known HF. Patients were categorized 'non-obese' BMI 18.5-29.9 kg/m2(n = 273) and 'obese' BMI ≥ 30 kg/m2(n = 119). The diagnosis of HF required signs, symptoms, and abnormal echocardiography. NT-proBNP, MR-proANP, MR-proADM, and copeptin were analyzed. Results: Obese patients were younger, had a higher prevalence of diabetes and chronic kidney disease, but a lower prevalence of atrial fibrillation. A total of 39 (14.3%) non-obese and 26 (21.8%) obese patients were diagnosed with HF. In obese patients, HF was not associated with higher plasma concentrations of NT-proBNP (Estimate: 0.063; 95%CI: -0.037-1.300; P = 0.064), MR-proANP (Estimate: 0.207; 95%CI: -0.101-0.515; P = 0.187), MR-proADM (Estimate: 0.112; 95%CI: -0.047-0.271; P = 0.168), or copeptin (Estimate: 0.093; 95%CI: -0.333-0.518; P = 0.669). Additionally, obese patients with HF had lower plasma concentrations of NT-proBNP (Estimate: -0.998; 95%CI: -1.778-0.218; P = 0.012), and MR-proANP (Estimate: -0.488; 95%CI: -0.845-0.132; P = 0.007) compared to non-obese patients with HF, whereas plasma concentrations of MR-proADM (Estimate: 0.066; 95%CI: -0.119-0.250; P = 0.484) and copeptin (Estimate: 0.140; 95%CI: -0.354-0.633; P = 0.578) were comparable. Conclusions: Patients with obe

Published
2020

25. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure:the Copenhagen heart failure risk study

Author

Gaborit, Freja Stoltze, Kistorp, Caroline, Kümler, Thomas, Hassager, Christian, Tønder, Niels, Iversen, Kasper, Hansen, Pernille Mørk, Kamstrup, Pia Rørbaek, Faber, Jens, Køber, Lars, Schou, Morten, Gaborit, Freja Stoltze, Kistorp, Caroline, Kümler, Thomas, Hassager, Christian, Tønder, Niels, Iversen, Kasper, Hansen, Pernille Mørk, Kamstrup, Pia Rørbaek, Faber, Jens, Køber, Lars, and Schou, Morten

Abstract

Background: Amino-terminal-pro-B-type-natriuretic-peptide (NT-proBNP) is a diagnostic biomarker for heart failure (HF), but plasma concentrations are influenced by numerous factors. Mid-regional-pro-atrial-natriuretic-peptide (MR-proANP) have comparable diagnostic value in acute HF. However, data are lacking in the non-acute setting. This study sought to assess the diagnostic utility of MR-proANP in outpatients with a high risk of HF. Methods: This prospective study included 399 outpatients. Inclusion criteria were: age ≥ 60 years, ≥1 risk factor for HF (diabetes, chronic kidney disease, vascular disease, atrial fibrillation, hypertension), without known or suspected HF. Unrecognized HF was diagnosed based on clinical signs, patient-reported symptoms and echocardiography. Plasma concentrations of MR-proANP and NT-proBNP were analysed. Results: In total, 65 patients were diagnosed with HF or asymptomatic left ventricular systolic dysfunction (N = 12 LVEF ≤ 40%, N = 7 LVEF > 40% to ≤50%, N = 46 LVEF > 50%). Both MR-proANP (odds-ratio: 1.77; 95% CI:1.16–2.72; p = 0.009) and NT-proBNP (odds-ratio: 1.49; 95% CI:1.22–1.82; p < 0.001) were associated with HF. Area under receiver-operator characteristics curve (AUC) for the diagnosis of HF or asymptomatic left ventricular systolic dysfunction was higher for MR-proANP (AUC = 0.886; p < 0.001) and NT-proBNP (AUC = 0.910; p < 0.001) compared to patient-reported symptoms of HF (AUC = 0.830), but NT-proBNP added more diagnostic information compared to MR-proANP (p = 0.022). Conclusions: Both NT-proBNP and MR-proANP are useful biomarkers in the diagnosis of HF or asymptomatic left ventricular systolic dysfunction in a non-acute setting. However, NT-proBNP added more diagnostic information compared to MR-proANP.

Published
2020

27. Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study

Author

Gaborit, Freja Stoltze, primary, Kistorp, Caroline, additional, Kümler, Thomas, additional, Hassager, Christian, additional, Tønder, Niels, additional, Iversen, Kasper, additional, Kamstrup, Pia R., additional, Faber, Jens, additional, Køber, Lars, additional, and Schou, Morten, additional

Published
2020
Full Text
View/download PDF

28. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study

Author

Gaborit, Freja Stoltze, primary, Kistorp, Caroline, additional, Kümler, Thomas, additional, Hassager, Christian, additional, Tønder, Niels, additional, Iversen, Kasper, additional, Hansen, Pernille Mørk, additional, Kamstrup, Pia Rørbaek, additional, Faber, Jens, additional, Køber, Lars, additional, and Schou, Morten, additional

Published
2020
Full Text
View/download PDF

32. Risk of recurrence and duration of anticoagulant treatment after deep venous thromboembolism and pulmonary embolism

Author

Comuth, Willemijn, Münster, Anna-Marie Bloch, Kümler, Thomas, Hellfritzsch, Maja, Larsen, Sanne Bøjet, Hansen, Morten Lock, and Grove, Erik Lerkevang

Abstract

If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients' preferences should be considered.

Published
2019

33. Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Left-Sided Heart Valve Surgery

Author

Butt, Jawad Haider, Olesen, Jonas Bjerring, Gundlund, Anna, Kümler, Thomas, Olsen, Peter Skov, Havers-Borgersen, Eva, Aagaard, David Thein, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, Køber, Lars, Fosbøl, Emil Loldrup, Butt, Jawad Haider, Olesen, Jonas Bjerring, Gundlund, Anna, Kümler, Thomas, Olsen, Peter Skov, Havers-Borgersen, Eva, Aagaard, David Thein, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, Køber, Lars, and Fosbøl, Emil Loldrup

Abstract

Importance: New-onset postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery. However, data on the long-term risk of thromboembolism in patients who develop POAF after heart valve surgery are conflicting. In addition, data on stroke prophylaxis in this setting are lacking.Objective: To assess the long-term risk of thromboembolism in patients developing new-onset POAF after isolated left-sided heart valve surgery relative to patients with nonsurgical, nonvalvular atrial fibrillation (NVAF).Design, Setting, and Participants: This observational cohort study was conducted from January 1, 2000, through December 31, 2015, using Danish nationwide registries and the Eastern Danish Heart Surgery Database. Patients who developed POAF after isolated left-sided heart valve surgery (bioprosthetic aortic or mitral valve replacement and/or aortic or mitral valve repair) from 2000 through 2015 were included. These patients were matched with patients with nonsurgical NVAF in a 1:3 ratio by age, sex, heart failure, hypertension, diabetes, a history of thromboembolism, ischemic heart disease, and year of diagnosis. Data analyses took place from January to March 2019.Main Outcomes and Measures: Rates of thromboembolism.Results: Of the 1587 patients who underwent isolated left-sided heart valve surgery, 741 patients (46.7%) developed POAF during admission. Of the 712 patients with POAF who were eligible for matching, 675 patients were matched with 2025 patients with NVAF and made up the study population. In the matched study population, the median age was 71 (interquartile range, 65-77) years, and 1600 (59.3%) were men. Oral anticoagulation therapy was initiated within 30 days postdischarge in 420 patients with POAF (62.9%) and in 1030 patients with NVAF (51.4%). The crude incidence rates of thromboembolism were 21.9 (95% CI, 17.4-27.6) and 17.7 (95% CI, 15.2-20.6) events per 1000 person-years for patients with POAF and patien

Published
2019

34. Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli

Author

Comuth, Willemijn, Münster, Anna-Marie Bloch, Kümler, Thomas, Hellfritzsch, Maja, Larsen, Sanne Bøjet, Hansen, Morten Lock, Grove, Erik Lerkevang, Comuth, Willemijn, Münster, Anna-Marie Bloch, Kümler, Thomas, Hellfritzsch, Maja, Larsen, Sanne Bøjet, Hansen, Morten Lock, and Grove, Erik Lerkevang

Abstract

If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients' preferences should be considered.

Published
2019

35. Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant-Danish nationwide cohort study

Author

Gundlund, A., Kümler, Thomas, Bonde, Anders Nissen, Butt, Jawad Haider, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, Køber, Lars, Olesen, Jonas Bjerring, Fosbøl, Emil Loldrup, Gundlund, A., Kümler, Thomas, Bonde, Anders Nissen, Butt, Jawad Haider, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, Køber, Lars, Olesen, Jonas Bjerring, and Fosbøl, Emil Loldrup

Abstract

Objectives We compared long-term outcomes in patients with atrial fibrillation (AF) with and without a secondary precipitant. Design and setting Retrospective cohort study based on Danish nationwide registries. Participants Patients with AF with and without secondary precipitants (1996-2015) were matched 1:1 according to age, sex, calendar year, CHA 2 DS 2-VASc score and oral anticoagulation therapy (OAC), resulting in a cohort of 39 723 patients with AF with a secondary precipitant and the same number of patients with AF without a secondary precipitant. Secondary precipitants included alcohol intoxication, thyrotoxicosis, myocardial infarction, surgery and infection in conjunction with AF. Primary and secondary outcomes The primary outcome in this study was thromboembolic events. Secondary outcomes included AF rehospitalisation and death. Long-term risks of outcomes were examined by multivariable Cox regression analysis. Results The most common precipitants were infection (55.0%), surgery (13.2%) and myocardial infarction (12.0%). The 5-year absolute risk of thromboembolic events (taking death into account as a competing risk) in patients with AF grouped according to secondary precipitants were 8.3% (alcohol intoxication), 8.5% (thyrotoxicosis), 12.1% (myocardial infarction), 11.6% (surgery), 12.2% (infection), 10.1% (>1 precipitant) and 12.3% (no secondary precipitant). In the multivariable analyses, AF with a secondary precipitant was associated with the same or an even higher thromboembolic risk than AF without a secondary precipitant. One exception was patients with AF and thyrotoxicosis: those not initiated on OAC therapy carried a lower thromboembolic risk the first year of follow-up than matched patients with AF without a secondary precipitant and no OAC therapy. Conclusions In general, AF with a secondary precipitant was associated with the same thromboembolic risk as AF without a secondary precipitant. Consequently, this study highlights the need for

Published
2019

36. Prevalence of early stages of heart failure in an elderly risk population:The Copenhagen Heart Failure Risk Study

Author

Gaborit, Freja Stoltze, Kistorp, Caroline, Kümler, Thomas, Hassager, Christian, Tønder, Niels, Køber, Lars, Hansen, Pernille Mørk, Kamstrup, Pia Rørbæk, Faber, Jens, Iversen, Kasper Karmark, Schou, Morten, Gaborit, Freja Stoltze, Kistorp, Caroline, Kümler, Thomas, Hassager, Christian, Tønder, Niels, Køber, Lars, Hansen, Pernille Mørk, Kamstrup, Pia Rørbæk, Faber, Jens, Iversen, Kasper Karmark, and Schou, Morten

Abstract

Aims To describe the prevalence of heart failure (HF) stages in elderly outpatients with risk factors for HF but without known HF, and characterise the clinical, biochemical and echocardiographic findings in each stage. Background Early stages of HF are underdiagnosed; nevertheless, they are associated with an increased risk of hospitalisation and increased mortality. The prevalence of HF stages in elderly high-risk patients is unknown. Methods A total of 400 patients were consecutively included: ≥60 years old, ≥1 risk factor for HF (diabetes, chronic kidney disease, cardiovascular disease, atrial fibrillation, hypertension), and without known or suspected HF. HF stages were defined as the following: Stage A (risk factor for HF, normal echocardiography), stage B (abnormal echocardiography, without symptoms of HF) and stage C (abnormal echocardiography, symptoms of HF, clinical signs/increased plasma aminoterminal pro-B-type natriuretic peptide [NT-proBNP] concentrations). Results After thorough examination 44.25% of patients were categorised as HF stage A, 37.5% were HF stage B and 18.25% HF stage C. Those with higher stages of HF were older (p<0.001) and more often had atrial fibrillation (p=0.006). The median plasma NT-proBNP concentrations (pg/mL) were 132.5 for HF stage A, 275.5 for HF stage B and 400.0 for HF stage C (p<0.001). Detectable plasma troponin-I was more frequent with abnormal echocardiography: HF stage A 9.7%, HF stage B 27.3% and HF stage C 30.1% (p<0.001). HF stage C reported higher score on the Minnesota Living with Heart Failure Questionnaire (p<0.001). Conclusions In an elderly high-risk population without known or suspected HF, more than half were HF stage B or C. Higher stages of HF had increased plasma concentrations of NT-proBNP and troponin-I, besides a reduced quality of life. Focus on symptoms and signs of HF in this population are warranted.

Published
2019

37. Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Left-Sided Heart Valve Surgery

Author

Butt, Jawad Haider, primary, Olesen, Jonas Bjerring, additional, Gundlund, Anna, additional, Kümler, Thomas, additional, Olsen, Peter Skov, additional, Havers-Borgersen, Eva, additional, Aagaard, David Thein, additional, Gislason, Gunnar Hilmar, additional, Torp-Pedersen, Christian, additional, Køber, Lars, additional, and Fosbøl, Emil Loldrup, additional

Published
2019
Full Text
View/download PDF

40. Prevalence of early stages of heart failure in an elderly risk population: the Copenhagen Heart Failure Risk Study

Author

Gaborit, Freja Stoltze, primary, Kistorp, Caroline, additional, Kümler, Thomas, additional, Hassager, Christian, additional, Tønder, Niels, additional, Køber, Lars, additional, Hansen, Pernille Mørk, additional, Kamstrup, Pia Rørbæk, additional, Faber, Jens, additional, Iversen, Kasper Karmark, additional, and Schou, Morten, additional

Published
2019
Full Text
View/download PDF

41. Renal function at the time of a myocardial infarction maintains prognostic value for more than 10 years

Author

Gustafsson Finn, Kober Lars, Gislason Gunnar H, Kümler Thomas, Schou Morten, and Torp-Pedersen Christian

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background Renal function is an important predictor of mortality in patients with myocardial infarction (MI), but changes in the impact over time have not been well described. We examined the importance of renal function by estimated GFR (eGFR) and se-creatinine as an independent long-term prognostic factor. Methods Prospective follow-up of 6653 consecutive MI patients screened for entry in the Trandolapril Cardiac Evaluation (TRACE) study. The patients were analysed by Kaplan-Meier survival analysis, landmark analysis and Cox proportional hazard models. Outcome measure was all-cause mortality. Results An eGFR below 60 ml per minute per 1.73 m2, consistent with chronic renal disease, was present in 42% of the patients. We divided the patients into 4 groups according to eGFR. Overall, Cox proportional-hazards models showed that eGFR was a significant prognostic factor in the two groups with the lowest eGFR, hazard ratio 1,72 (confidence interval (CI) 1,56-1,91) in the group with the lowest eGFR. Using the eGFR group with normal renal function as reference, we observed an incremental rise in hazard ratio. We divided the follow-up period in 2-year intervals. Landmark analysis showed that eGFR at the time of screening continued to show prognostic effect until 16 years of follow-up. By multivariable Cox regression analysis, the prognostic effect of eGFR persisted for 12 years and of se-creatinine for 10 years. When comparing the lowest group of eGFR with the group with normal eGFR, prognostic significance was present in the entire period of follow-up with a hazard ratio between 1,97 (CI 1,65-2,35) and 1,35 (CI 0,99-1,84) in the 2-year periods. Conclusions One estimate of renal function is a strong and independent long-term prognostic factor for 10-12 years following a MI.

Published
2011
Full Text
View/download PDF

42. Diabetes is an independent predictor of survival 17 years after myocardial infarction: follow-up of the TRACE registry

Author

Torp-Pedersen Christian, Køber Lars, Gislason Gunnar H, and Kümler Thomas

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background In patients hospitalized for myocardial infarction, there are limited data examining the long-term prognostic effect of diabetes. The aim of this study was to systematically evaluate the development of diabetes as an independent long-term prognostic factor after myocardial infarction. Methods Prospective follow-up of 6676 consecutive MI patients screened for entry in the Trandolapril Cardiac Evaluation (TRACE) study. The patients were analysed by Kaplan-Meier survival analysis, landmark analysis and Cox proportional hazard models and outcome measure was all-cause mortality. Results The mortality in patients with diabetes was 82,7% at 10 years of follow-up and 91,1% at 15 years of follow-up, while patients without diabetes had a mortality of 60,2% at 10 years of follow-up and 72,9% at 15 years of follow-up (p < 0.0001). Landmark analysis continued to show prognostic significance of diabetes throughout the duration of follow-up. Multivariable Cox proportional-hazards model showed that the hazard ratio for death in patients with diabetes overall was 1.47 (95% confidence intervals (CI) 1.35-1.61) and varied between 1.19 (CI 1.04-1.37) and 2.13 (CI 1.33-3.42) in the 2-year periods of follow-up. Conclusions Diabetes is an important independent long-term prognostic factor after MI and continues to predict mortality even 17 years after index MI. This underscores the importance of aggressive diagnostic and therapeutic approach in diabetes patients with MI.

Published
2010
Full Text
View/download PDF

43. Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids

Author

Rasmussen, Jon J., Schou, Morten, Madsen, Per L., Selmer, Christian, Johansen, Marie L., Ulriksen, Peter S., Dreyer, Tina, Kümler, Thomas, Plesner, Louis L., Faber, Jens, Gustafsson, Finn, Kistorp, Caroline, Rasmussen, Jon J., Schou, Morten, Madsen, Per L., Selmer, Christian, Johansen, Marie L., Ulriksen, Peter S., Dreyer, Tina, Kümler, Thomas, Plesner, Louis L., Faber, Jens, Gustafsson, Finn, and Kistorp, Caroline

Abstract

Background: Illicit use of anabolic androgenic steroids (AAS) is associated with left ventricle (LV) systolic dysfunction and increased LV mass (LVM), but whether these findings persist in former AAS users has yet to be elucidated. The objective was to assess LV systolic function, LVM and myocardial fibrosis in current and former illicit AAS users compared with non-users. Methods: Community-based cross-sectional study among men, aged 18–50 years, involved in recreational resistance training. We included 37 current and 33 former illicit AAS users, geometric mean (95%CI), 30 (21; 44) months since AAS cessation, and 30 non-users as controls. We assessed myocardial function and structure using advanced echocardiography and cardiac MRI with late-gadolinium enhancement. Results: Mean (SE) LV global longitudinal strain (GLS) was impaired in former AAS users compared with non-users, −16.7 (0.5) versus −18.2 (0.4) %, P <.05. Mean (SE) LV ejection fraction (EF) was decreased, 51 (1) versus 58 (1) %, P <.001 and LV GLS impaired, −14.5 (0.4)%, P <.001, in current AAS users compared with non-users. Measures of LVM were increased in current AAS users compared with the other two groups, P <.001. Plasma total testosterone was independently associated with reduced LVEF (P =.049) and increased LVM/body surface area (P =.005) in multivariate linear regressions. Focal myocardial fibrosis was not detected in any participants and diffuse myocardial fibrosis, assessed using post-contrast T1-mapping time, did not differ among the three groups. Conclusions: Past illicit AAS use is associated with impaired LV GLS, suggesting subclinical cardiac systolic dysfunction years after AAS cessation.

Published
2018

44. Comparative thromboembolic risk in atrial fibrillation patients with and without a concurrent infection

Author

Gundlund, Anna, Kümler, Thomas, Olesen, Jonas Bjerring, Bonde, Anders Nissen, Gislason, Gunnar H, Torp-Pedersen, Christian, Køber, Lars, Fosbøl, Emil Loldrup, Gundlund, Anna, Kümler, Thomas, Olesen, Jonas Bjerring, Bonde, Anders Nissen, Gislason, Gunnar H, Torp-Pedersen, Christian, Køber, Lars, and Fosbøl, Emil Loldrup

Abstract

BACKGROUND: The aim of this study was to compare long-term thromboembolic risk in infection-related and non-infection-related atrial fibrillation (AF).METHODS: Using Danish nationwide registries, we identified patients with first-time AF from 1996-2015 and performed a retrospective cohort study. We did a 1:1 match (upon sex, age, calendar year, and oral anticoagulation (OAC) status at the beginning of follow-up) of patients with infection-related (concurrent discharge diagnosis code for infection) and non-infection-related AF. Long-term outcomes were examined using multivariable Cox regression analyses.RESULTS: Our study population comprised 48,644 patients equally distributed on infection-related and non-infection-related AF. In both groups, those initiated on OAC therapy were younger than those not initiated on OAC therapy (median age 77 years, interquartile range 69-83 versus median age 79 years, interquartile range 71-86). During the 1st year of follow up, infection-related AF was associated with an increased risk of thromboembolic events compared with non-infection-related AF: adjusted hazard ratio (HR) 1.44 (95% confidence interval (CI) 1.16-1.78) for those initiated on OAC therapy and HR 1.17 (95% CI 1.06-1.28) for those not initiated on OAC therapy. In both groups, OAC therapy was associated with better outcomes than no OAC therapy (HR of thromboembolic events 0.75 (95% CI 0.68-0.83) and HR 0.70 (95% CI 0.63-0.78) for patients with infection-related and non-infection-related AF, respectively).CONCLUSION: Infection was associated with an increased thromboembolic risk in patients with first-time AF. OAC therapy was associated with a similar risk-reduction in AF patients with and without a concurrent infection.

Published
2018

45. Exercise-induced left bundle branch block - A case report with stress-echocardiographic assessment

Author

Jensen, Jesper, Theilade, Juliane, Kümler, Thomas, Jensen, Jesper, Theilade, Juliane, and Kümler, Thomas

Abstract

We report the case of a 51-year-old male who presented with exertional chest discomfort and dyspnea concurring with an exercise-induced left bundle branch block (EI-LBBB). Possible underlying causes and treatment options are presented and discussed. The case represents the first stress-echocardiographic assessment of a case with EI-LBBB, performed in order to document a possible left ventricular dyssynchrony during the EI-LBBB and thereby the possible treatment option of biventricular pacemaker implantation.

Published
2018

46. The Changing Landscape for Stroke Prevention in AF Findings From the GLORIA-AF Registry Phase 2

Author

Huisman, Menno V., Rothman, Kenneth J., Paquette, Miney, Teutsch, Christine, Diener, Hans-Christoph, Dubner, Sergio J., Halperin, Jonathan L., Chang Sheng, Ma, Zint, Kristina, Elsaesser, Amelie, Bartels, Dorothee B., Lip, Gregory Y. H., Abban, Dzifa, Abdul, Nasser, Abelson, Mark, Ackermann, Alan, Adams, Fran, Adams, Luthando, Adragão, Pedro, Ageno, Walter, Aggarwal, Rajesh, Agosti, Sergio, Marin, Javier Aguila, Aguilar, Francisco, Aguilar Linares, Julio Alberto, Aguinaga, Luis, Ahmad, Zia, Ainsworth, Paul, Al Ghalayini, Kamal, Al Ismail, Saad, Alasfar, Abdelfatah, Alawwa, Abdul, Al-Dallow, Raed, Alderson, Lisa, Alexopoulos, Dimitrios, Ali, Abdullah, Ali, Malik, Aliyar, Pareed, Al-Joundi, Tammam, Al Mahameed, Soufian, Almassi, Hossein, Almuti, Khalid, Al-Obaidi, Mohamed, Alshehri, Mohamed, Altmann, Ute, Alves, Alvaro Rabelo, Al-Zoebi, Ayham, Amara, Walid, Amelot, Mathieu, Amjadi, Nima, Ammirati, Fabrizio, Andrawis, Nabil, Angoulvant, Denis, Annoni, Giorgio, Ansalone, Gerardo, Antonescu, Sorin Alexandru, Ariani, Mehrdad, Arias, Juan Carlos, Armero, Sébastien, Arora, Rohit, Arora, Chander, Ashcraft, William, Aslam, M. Shakil, Astesiano, Alfredo, Audouin, Philippe, Augenbraun, Charles, Aydin, S., Azar, Rabih, Azim, Abul, Aziz, Shahid, Backes, Luciano Marcelo, Baig, Mirza, Bains, Suchdeep, Bakbak, Asaad, Baker, Seth, Bakhtiar, Karim, Bala, Richard, Banayan, Jonathan, Bandh, Stellan, Bando, Shigenobu, Banerjee, Subhash, Bank, Alan, Barbarash, Olga, Barón, Gonzalo, Barr, Craig, Barrera, Carlos, Barton, John, Kes, Vanja Basic, Baula, Giovanni, Bayeh, Hamid, Bazargani, Nooshin, Behrens, Steffen, Bell, Alan, Benezet-Mazuecos, Juan, Benhalima, Bouziane, Berdagué, Philippe, Berg van den, B. J., Bergen van, P. F. M. M., Berngard, Edvard, Bernstein, Richard, Berrospi, Percy, Berti, Sergio, Bertomeu, Vicente, Berz, Andrea, Bettencourt, Paulo, Betzu, Robert, Beyer-Westendorf, Jan, Bhagwat, Ravi, Black, Toby, Blanco Ibaceta, Jorge Hugo, Bloom, Stephen, Blumberg, Edwin, Mario, Bo, Bockisch, Valerie, Bøhmer, Ellen, Bongiorni, Maria Grazia, Boriani, Giuseppe, Bosch, Ralph, Boswijk, D. J., Bott, Jochen, Bottacchi, Edo, Kalan, Marica Bracic, Brandes, Axel, Bratland, Bjørn, Brautigam, Donald, Breton, Nicolas, Brouwers, P. J. A. M., Browne, Kevin, Bruguera, Jordi, Brunehaut, Myriam, Brunschwig, Claude, Buathier, Hervé, Buhl, Aurélie, Bullinga, John, Butcher, Kenneth, Cabrera Honorio, Jose Walter, Caccavo, Alberto, Cadinot, Didier, Cai, Shanglang, Calvi, Valeria, Camm, John, Candeias, Rui, Capo, James, Capucci, Alessandro, Cardoso, Juliano Novaes, Duarte Vera, Yan Carlos, Carlson, Brian, Carvalho, Paula, Cary, Susanna, Casanova, Rene, Casu, Gavino, Cattan, Simon, Cavallini, Claudio, Cayla, Guillaume, Cha, Tae Joon, Cha, Kwang Soo, Chaaban, Said, Chae, Jei Keon, Challappa, Krishnan, Chand, Sunil, Chandrashekar, Harinath, Chang, Mark, Charbel, Paul, Chartier, Ludovic, Chatterjee, Kausik, Cheema, Aamir, Chen, Shih-Ann, Chevallereau, Pierre, Chiang, Fu-Tien, Chiarella, Francesco, Chih-Chan, Lin, Cho, Yong Keun, Choi, Dong Ju, Chouinard, Guy, Danny, Null, Chow, Hoi Fan, Chrysos, Dimitrios, Chumakova, Galina, José Roberto Chuquiure Valenzuela, Eduardo Julián, Cieza-Lara, Tomas, Nica, Violeta Cindea, Ciobotaru, Vlad, Cislowski, David, Citerne, Olivier, Claus, Matthias, Clay, Anthony, Clifford, Piers, Cohen, Serge, Cohen, Andrew, Colivicchi, Furio, Collins, Rónán, Compton, Steve, Connors, Sean, Conti, Alberto, Buenostro, Gabriel Contreras, Coodley, Gregg, Cooper, Martin, Corbett, Lynn, Corey, Oran, Coronel, Julián, Corrigan, John, Cotrina Pereyra, Rosa Ysabel, Cottin, Yves, Coutu, Benoit, Cracan, Aurel, Crean, Peter, Crenshaw, James, Crijns, H. J. G. M., Crump, Charles, Cucher, Fred, Cudmore, David, Cui, Lianqun, Culp, John, Darius, Harald, Dary, Patrick, Dascotte, Olivier, Dauber, Ira, Davee, Thomas, Davies, Ruth, Davis, Gershan, Davy, Jean-Marc, Dayer, Mark, De La Briolle, Axel, de Mora, Manuel, De Teresa, Eduardo, De Wolf, Luc, Decoulx, Eric, Deepak, Sasalu, Defaye, Pascal, Del-Carpio Munoz, Freddy, Brkljacic, Diana Delic, Deluche, Laurent, Destrac, Sylvain, Deumite, N. Joseph, Di Legge, Silvia, Dibon, Olivier, Diemberger, Igor, Dillinger, Jean, Dionísio, Pedro, Naydenov, Stefan, Dotani, Imran, Dotcheva, Elena, D'Souza, Anthony, Dubrey, Simon, Ducrocq, Xavier, Dupljakov, Dmitry, Duthinh, Vuong, Dutra, Oscar Pereira, Dutta, Dipankar, Duvilla, Nathalie, Johnny, Dy, Dziewas, Rainer, Eaton, Charles, Eaves, William, Ebinger, Matthew, Eck van, J. W. M., Edwards, Tim, Egocheaga, Isabel, Ehrlich, Clifford, Eisenberg, Steven, El Hallak, Abdel, El Jabali, Adnan, El Mahmoud, Rami, El Shahawy, Mahfouz, Eldadah, Zayd, Elghelbazouri, Fouad, Elhag, Omar, El-Hamdani, Mehiar, Elias, Darlene, Ellery, Adam, El-Sayed, Hassan, Elvan, A., Erickson, Bernard, Espaliat, Eric, Essandoh, Louis, Everington, Tamara, Evonich, Rudolph, Ezhov, Andrey, Fácila, Lorenzo, Farsad, Ramin, Fayard, Maxime, Fedele, Francesco, Gomes Ferreira, Luis Gustavo, Ferreira, Daniel, Santos, José Ferreira, Ferrier, Anna, Finsen, Alexandra, First, Brian, Fisher, Raymond, Floyd, John, Folk, Thomas, Fonseca, Catarina, Fonseca, Luisa, Forman, Steven, Forsgren, Magnus, Foster, Malcolm, Foster, Nathan, Frais, Michael, Frandsen, Brad, Frappé, Thierry, Freixa, Ramon, French, William, Freydlin, Marina, Frickel, Siegfried, Fruntelata, Ana Gabriela, Fujii, Shigeru, Fujino, Yusuke, Fukunaga, Hiroshi, Furukawa, Yutaka, Gabelmann, Matthias, Gabris, Michael, Gadsbøll, Niels, Galin, Pavel, Galinier, Michel, Ganim, Ricky, Garcia, Ronnie, Quintana, Antonio Garcia, Gartenlaub, Olivier, Genz, Conrad, Georger, Frédéric, Georges, Jean-Louis, Georgeson, Steven, Ghanbasha, Ali, Giedrimas, Evaldas, Gierba, Mariusz, Gillespie, Eve, Giniger, Alberto, Gkotsis, Alexandros, Gmehling, Joachim, Gniot, Jacek, Goethals, Peter, Goldberg, Ronald, Goldmann, Britta, Goldscher, David, Golitsyn, Sergey, Gomez Lopez, Efrain Alonso, Gomez Mesa, Juan Esteban, Gonzalez, Efrain, Cocina, Emilio Gonzalez, Juanatey, Carlos Gonzalez, Gorbunov, Vladimir, Gordon, Brian, Gorka, Hervé, Gornick, Charles, Gorog, Diana, Goss, Franz, Götte, Andreas, Goube, Pascal, Goudevenos, Ioannis, Goulden, Dudley, Graham, Brett, Grande, Angel, Greco, Cesare, Green, Martin, Greer, Gerald, Gremmler, Uwe, Grena, Paul, Grinshstein, Yuriy, Grond, Martin, Gronda, Edoardo, Grondin, Francois, Grönefeld, Gerian, Groot de, J. R., Guardigli, Gabriele, Guarnieri, Thomas, Caiedo, Carolina Guevara, Guignier, Alexandre, Gulizia, Michele, Gumbley, Michael, Gupta, Dhiraj, Hack, Terrence, Haerer, Winfried, Hakas, Joseph, Hall, Christian, Hampsey, James, Hananis, Georgios, Hanbali, Basel, Handel, Franklin, Hargrove, Joe, Hargroves, David, Harris, Kenneth, Hartley, David, Haruna, Tetsuya, Hata, Yoshiki, Hayek, Emil, Healey, Jeff, Hearne, Steven, Heggelund, Geir, Hemels, M. E. W., Hemery, Yann, Henein, Sam, Henz, Benhur, Her, Sung-Ho, Hermany, Paul, Hernandes, Mauro Esteves, Higashino, Yorihiko, Hill, Michael, Hisadome, Tetsuo, Hishida, Eiji, Hitchcock, James, Hoffer, Etienne, Hoghton, Matthew, Holmes, Clare, Hong, Suk Keun, Houppe Nousse, Marie-Paule, Howard, Victor, Hsu, Li Fern, Huang, Chi-Hung, Huckins, David, Huehnergarth, Kier, Huizenga, A., Huntley, Richard, Hussein, Gamal, Hwang, Gyo-Seung, Igbokidi, Oyidie, Iglesias, Ignacio, Ikpoh, Margaret, Imberti, Davide, Ince, Hüseyin, Indolfi, Ciro, Ionova, Tatiana, John, Ip, Irles, Didier, Iseki, Harukazu, Ismail, Younus, Israel, Noah, Isserman, Steven, Iteld, Bruce, Ivanchura, Galina, Iyer, Ramakrishnan, Iyer, Venkat, Iza Villanueva, Ruben Omar, Jackson-Voyzey, Ewart, Jaffrani, Naseem, Jäger, Frank, Jain, Manish, James, Martin, Jamon, Yann, Jang, Sung Won, Pereira Jardim, Cesar Augusto, Jarmukli, Nabil, Jeanfreau, Robert, Jenkins, Ronald, Jiang, Xianyan, Jiang, Heng, Jiang, Tiemin, Jiang, Nan, Jimenez, Javier, Jobe, Robert, Joffe, Ian, Johansson, Bengt, Jones, Nick, Moura Jorge, Jose Carlos, Jouve, Bernard, Jundi, Mayar, Jung, Werner, Jung, Byung Chun, Jung, Kyung Tae, Kabbani, Samer, Kabour, Ameer, Kafkala, Chrystalenia, Kajiwara, Koji, Kalinina, Larisa, Kampus, Priit, Kanda, Junji, Kapadia, Shaival, Karim, Amin, Karolyi, Laszlo, Kashou, Hisham, Kastrup, Andreas, Katsivas, Apostolos, Kaufman, Elizabeth, Kawai, Kazuya, Kawajiri, Kenji, Kazmierski, John, Keeling, Phil, Kerfes, Galal Ali, Kerr Saraiva, José Francisco, Ketova, Galina, Khaira, Ajit, Khalid, Muhammad, Khludeeva, Elena, Khripun, Aleksey, Kim, Doo Il, Kim, Dae Kyeong, Kim, Nam Ho, Kim, Ki Seok, Kim, Young-Hoon, Kim, Jin bae, Kim, June Soo, Kim, Jeong Su, Kinova, Elena, Klein, Alexander, Kleinschnitz, Christoph, Kmetzo, James, Kneller, G. Larsen, Knezevic, Aleksandar, Koch, Stanley, Koenig, Kai, Angela Koh, Su Mei, Köhrmann, Martin, Koons, Jay, Korabathina, Ravikiran, Korennova, Olga, Koschutnik, Martin, Kosinski, Edward, Kovacic, Dragan, Kowalczyk, Jacek, Koziolova, Natalya, Kragten, J. A., Krause, Lars Udo, Kreidieh, Imad, Krenning, B. J., Krishnaswamy, Kannappan, Krysiak, Waldemar, Kuck, Karl-Heinz, Kumar, Somnath, Kümler, Thomas, Kuniss, Malte, Kuo, Jen-Yuan, Küppers, Achim, Kurrelmeyer, Karla, Kwan, Tak, Kyo, Eisho, Labovitz, Arthur, Lacroix, Alain, Lam, Andy, Lanas Zanetti, Fernando Tomas, Landau, Charles, Landini, Giancarlo, Lang, Wilfried, Larsen, Torben Bjerregaard, Laske, Volker, Lavandier, Karine, Law, Nicki, Lee, Moon Hyoung, Lee, Daniel, Leitão, Ana, Lejay, Dominique, Lelonek, Malgorzata, Lenarczyk, Radoslaw, Leprince, Patrick, Lequeux, Benoit, Leschke, Matthias, Ley, Nicolas, Zicheng, Li, Yansheng, Li, Xiaodong, Li, Zhanquan, Li, Weihua, Li, Liang, Jianqiu, Lieber, Ira, Lillestol, Michael, Limon Rodriguez, Ramon Horacio, Lin, Hailong, Lip, Gregory, Litchfield, Jennifer, Liu, Zhitao, Liu, Xuebo, Liu, Yalin, Liu, Feng, Liu, Wenhui, Llamas Esperon, Guillermo Antonio, Llisterri, Jose Luis, Ted, Lo, Eric, Lo, Lobos, Jose Maria, Lodde, Bernhard-Paul, Loiselet, Philippe, López-Sendón, José, Lorga Filho, Adalberto Menezes, Lori, Ido, Luo, Ming, Lupovitch, Steven, Lyrer, Philippe, Zuhairy, Hamed M., Changsheng, Ma, Genshan, Ma, Hong, Ma, Madariaga, Irene, Maeno, Koji, Magnin, Dominique, Mahmood, Shahid, Mahood, Karen, Maid, Gustavo, Mainigi, Sumeet, Makaritsis, Konstantinos, Maldonado Villalon, José Arturo, Malhotra, Rohit, Malik, Amir, Mallecourt, Catherine, Mallik, Rajiv, Manning, Rickey, Manolis, Athanasios, Mantas, Ioannis, Manzur Jattin, Fernando Gabriel, Marcionni, Niccolo', Marín, Francisco, Santana, Antonio Martín, Martinez, Jorge, Martinez, Luis, Maskova, Petra, Hernández, Norberto Matadamas, Matskeplishvili, Simon, Matsuda, Katsuhiro, Mavri, Alenka, May, Erik, Mayer, Nolan, Mazon, Pilar, Mcclure, John, Mccormack, Terry, Mcgarity, William, Mcguire, Michael, Mcintyre, Hugh, Mclaughlin, Paul, Mclaurin, Brent, Medina Palomino, Feliz Alvaro, Mehta, Paresh, Mehzad, Reza, Meinel, Andreas, Melandri, Francesco, Mena, Amparo, Meno, Hirosi, Menzies, Dhananjai, Metcalf, Kneale, Meyer, Beat, Miarka, Jacek, Mibach, Frank, Michalski, Dominik, Michel, Patrik, Chreih, Rami Mihail, Mikdadi, Ghiath, Mikhail, Magdy, Mikus, Milan, Milicic, Davor, Militaru, Constantin, Miller, Gary, Milonas, Christos, Minescu, Bogdan, Mintale, Iveta, Miralles, Aurélien, Mirault, Tristan, Mistry, Dinesh, Mitchell, George, Miu, Nicoleta Violeta, Miyamoto, Naomasa, Moccetti, Tiziano, Mohammed, Akber, Nor, Azlisham Mohd, Molina de Salazar, Dora Ines, Molon, Giulio, Molony, David, Mondillo, Sergio, Mont, Lluis, Moodley, Rajendra, Moore, Roger, Ribeiro Moreira, Dalmo Antonio, Mori, Kiyoo, Moriarty, Andrew, Morka, Jacek, Moschos, Nikitas, Mota Gomes, Marco Antônio, Mousallem, Nicolas, Moya, Angel, Mügge, Andreas, Mulhearn, Thomas, Muller, Jean-Joseph, Muresan, Carmen Manuela, Muse, Derek, Musial, Wlodzimierz, Musumeci, Francesco, Nadar, Venkatesh, Nageh, Thuraia, Nair, Priya, Nakagawa, Hidemitsu, Nakamura, Yuichiro, Nakayama, Toru, Nam, Ki-Byeong, Napalkov, Dmitry, Natarajan, Indira, Nayak, Hemal, Nechvatal, Libor, Neiman, James, Nerheim, Pamela, Neuenschwander, Fernando Carvalho, Nishida, Kunihiro, Nizov, Alexey, Novikova, Tatiana, Novo, Salvatore, Nowalany-Kozielska, Ewa, Nsah, Emmanuel, Nunez Fragoso, Juan Carlos, Nyvad, Ole, de Los Rios Ibarra, Manuel Odin, O'Donnell, Martin, O'Donnell, Philip, Dong Jin, Oh, Yong Seog, Oh, Daniel Oh, Chia Theng, O'Hara, Gilles, Oikonomou, Kostas, Olalla, Juan Jose, Olivari, Zoran, Oliver, Richard, Olympios, Christoforos, Osborne, John, Osca, Joaquin, Osman, Raed, Osunkoya, Abayomi, Padanilam, Benzy, Panchenko, Elizaveta, Pandey, A. Shekhar, Vicenzo de Paola, Angelo Amato, Paraschos, Alexander, Pardell, Herbert, Park, Hyung Wook, Park, Jong Sung, Parkash, Ratika, Parker, Ian, Parrens, Eric, Parris, Robert, Passamonti, Enrico, Patel, Jaydutt, Patel, Rajesh, Pentz, William H., Persic, Viktor, Perticone, Francesco, Peters, Patrick, Petkar, Sanjiv, Pezo, Luis Felipe, Pham, David, Cao Phai, Gérald Phan, Phlaum, Stephen, Pineau, Julien, Pineda-Velez, Armando, Pini, Riccardo, Pinter, Arnold, Pinto, Fausto, Pirelli, Salvatore, Pivac, Nediljko, Pizzini, Attilia Maria, Pocanic, Darko, Calin Podoleanu, Cristian Gheorghe, Polanczyk, Carisi Anne, Polasek, Petr, Poljakovic, Zdravka, Pollock, Stewart, Polo, Jose, Poock, James, Poppert, Holger, Porro, Yamile, Pose, Antonio, Poulain, François, Poulard, Jean-Ernst, Pouzar, Joe, Povolny, Petr, Pozzer, Domingo, Pras, Athanasios, Prasad, Neeraj, Prevot, Sébastien, Protasov, Konstantin, Prunier, Laurent, Puleo, John, Pye, Maurice, Qaddoura, Fatma, Quedillac, Jean-Michel, Raev, Dimitar, Rahimi, Sidiqullah, Raisaro, Arturo, Rama, Bhola, Ranadive, Nandkishore, Randall, Katie, Ranjith, Naresh, Raposo, Nuno, Rashid, Haroon, Raters, Christa, Rauch-Kroehnert, Ursula, Rebane, Thomas, Regner, Stefan, Renzi, Michael, Reyes Rocha, Miguel Agustin, Reza, Shabbir, Ria, Luigi, Richter, Dimitrios, Rickli, Hans, Rickner, Kyle, Rieker, Werner, Rigo, Fausto, Ripoll, Tomas, Fonteles Ritt, Luiz Eduardo, Roberts, Douglas, Pascual, Carlos Rodríguez, Briones, Ignacio Rodriguez, Reyes, Humberto Rodriguez, Roelke, Marc, Roman, Mark, Romeo, Francesco, Ronner, E., Ronziere, Thomas, Rooyer, F. A., Rosenbaum, David, Roth, Sherryn, Rozkova, Nadezda, Rubacek, Miroslav, Rubalcava, Frank, Rubanenko, Olesya, Rubin, Andrew, Borret, Mariano Ruiz, Rybak, Karin, Sabbour, Hani, Morales, Oscar Saenz, Sakai, Tetsuo, Salacata, Abraham, Salecker, Ilsbe, Salem, Adrien, Salfity, Marwan, Salguero, Rafael, Salvioni, Alessandro, Samson, Mercedes, Sanchez, Gregorio, Sandesara, Chirag, Saporito, Wladmir Faustino, Sasaoka, Taishi, Sattar, Payman, Savard, Daniel, Scala, Pierre-Jean, Scemama, Jacques, Schaupp, Thierry, Schellinger, Peter, Scherr, Carlos, Schmitz, Karl-Heinz, Schmitz, Bettina, Schmitz, Lisa, Schnitzler, Robert, Schnupp, Steffen, Schoeniger, Peter, Schön, Norbert, Schuster, Stefan, Schwimmbeck, Peter, Seamark, Clare, Seebass, Ruediger, Seidl, Karl-Heinz, Seidman, Barry, Sek, Jaroslaw, Sekaran, Lakshmanan, Seko, Yoshinori, Sepulveda Varela, Pablo Andres, Sevilla, Begoña, Shah, Vinay, Shah, Anil, Shah, Neerav, Shah, Aman, Shanes, Jeffrey, Sharareh, Ali, Sharma, Vijay Kumar, Shaw, Louise, Shimizu, Yutaka, Shimomura, Hideki, Shin, Dong Gu, Shin, Eun-Seok, Shite, Junya, Shoukfeh, Mohammad, Shoultz, Charles, Silver, Frank, Sime, Iveta, Simmers, T. A., Singal, Dinesh, Singh, Narendra, Siostrzonek, Peter, Sirajuddin, Mohiburrahman, Skeppholm, Mika, Smadja, Didier, Smith, Richard, Smith, David, Soda, Hassan, Sofley, C. Wilson, Sokal, Adam, Sotolongo, Rodolfo, de Souza, Olga Ferreira, Sparby, Jon Arne, Spinar, Jindrich, Sprigings, David, Spyropoulos, Alex, Stakos, Dimitrios, Steinberg, Alon, Steinwender, Clemens, Stergiou, Georgios, Stites, H. William, Stoikov, Anastas, Strasser, Ruth, Streb, Witold, Styliadis, Ioannis, Guohai, Su, Xi, Su, Suarez, Rafael Martin, Sudnik, Wanda, Sueyoshi, Atsushi, Sukles, Kai, Sun, Li, Suneja, Randeep, Svensson, Peter, Ziekenhuis, Antonius, Szavits-Nossan, Janko, Taggeselle, Jens, Takagi, Yuichiro, Takhar, Amrit, Tallet, Julio, Tamm, Angelika, Tanaka, Shozo, Tanaka, Katsumi, Tang, Aylmer, Tang, Sherman, Tassinari, Tiziana, Tayama, Shinji, Tayebjee, Muzahir, Tebbe, Ulrich, Teixeira, Jose, Tesloianu, Dan Nicolae, Tessier, Pascal, The, S. H. K., Thevenin, Jérome, Thomas, Harold, Timsit, Serge, Topkis, Robert, Torosoff, Mikhail, Touze, Emmanuel, Traissac, Thalie, Trendafilova, Elina, Troyan, Barry, Tsai, Wenchi Kevin, Tse, Hung Fat, Tsutsui, Hiroshi, Tsutsui, Takashi, Tuininga, Y. S., Turakhia, Minang, Turk, Samir, Turner, Wayne, Tveit, Arnljot, Twiddy, Shannon, Tytus, Richard, Ukrainski, Gerald, Valdovinos Chavez, Salvador Bruno, Van De Graaff, Eric, Vanacker, Peter, Vardas, Panagiotis, Vargas, Michael, Vassilikos, Vassilios, Vazquez, Juan, Venkataraman, Asok, Verdecchia, Paolo, Vester, Ernst Günter, Vial, Hubert, Vinereanu, Dragos, Vlastaris, Anthony, Vogel, Craig, vom Dahl, Jürgen, von Mering, Matthias, Vora, Kishor, Wakefield, Paul, Walia, Jasjit, Walter, Thomas, Wang, Mingsheng, Wang, Ningfu, Wang, Feng, Wang, Xinhua, Wang, Zulu, Wang, Kuo-Yang, Watanabe, Kouki, Wei, Jeanne, Weimar, Christian, Weinrich, Renate, Wen, Ming-Shien, Wheelan, Kevin, Wicke, Jens, Wiemer, Marcus, Wild, Beate, Wilke, Andreas, Willems, Stephan, Williams, Marcus, Williams, David, Winkler, Andreas, Wirtz, Jost Henner, Witzenbichler, Bernhard, Wong, Danny H. K., Lawrence Wong, Ka Sing, Wong, Brian, Wozakowska-Kaplon, Beata, Zhaohui, Wu, Shulin, Wu, Wyatt, Nell, Yong, Xu, Xiangdong, Xu, Yamada, Akira, Yamamoto, Kazuya, Yamanoue, Hiroki, Yamashita, Takeshi, Bryan Yan, Ping Yen, Yang, Yanmin, Yang, Tianlun, Yao, Jing, Yarlagadda, Chakri, Yeh, Kuo-Ho, Yotov, Yoto, Yvorra, Serge, Zahn, Ralf, Zamorano, José, Zanini, Roberto, Zarich, Stuart, Zebrack, James, Zenin, Sergei, Zeuthen, Elisabeth Louise, Zhang, Xingwei, Zhang, Quansan, Zhang, Dadong, Zhang, Donghui, Zhang, Huanyi, Zhao, Shuiping, Zhao, Xinwen, Zheng, Yang, Zheng, Qiangsun, Zhou, Jing, Zhou, Jian, Zimmermann, Sergio Luiz, Zimmermann, Rainer, Zukerman, L. Steven, and Zwaan van der, C.

Subjects
oral anticoagulation, cross-sectional studies, registries, antithrombins, registry, stroke, internationality, prospective studies, aged, cardiology and cardiovascular medicine, female, male, fibrinolytic agents, middle aged, dabigatran, atrial fibrillation, humans
Published
2017

47. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study.

Author

Gundlund, Anna, Olesen, Jonas Bjerring, Butt, Jawad H, Christensen, Mathias Aagaard, Gislason, Gunnar H, Torp-Pedersen, Christian, Køber, Lars, Kümler, Thomas, and Fosbøl, Emil Loldrup

Abstract

Aims Thromboprophylaxis guidelines for patients with concurrent atrial fibrillation (AF) during infections are unclear and not supported by data. We compared 1-year outcomes in patients with infection-related AF and infection without AF. Methods and results By crosslinking Danish nationwide registry data, AF naïve patients admitted with infection (1996–2016) were identified. Those with AF during the infection (infection-related AF) were matched 1:3 according to age, sex, type of infection, and year with patients with infection without AF. Outcomes (AF, thromboembolic events) were assessed by multivariable Cox regression. The study population comprised 30 307 patients with infection-related AF and 90 912 patients with infection without AF [median age 79 years (interquartile range 71–86), 47.6% males in both groups]. The 1-year absolute risk of AF and thromboembolic events were 36.4% and 7.6%, respectively (infection-related AF) and 1.9% and 4.4%, respectively (infection without AF). In the multivariable analyses, infection-related AF was associated with an increased long-term risk of AF and thromboembolic events compared with infection without AF: hazard ratio (HR) 25.98, 95% confidence interval (CI) 24.64–27.39 for AF and HR 2.10, 95% CI 1.98–2.22 for thromboembolic events. Further, differences in risks existed across different subtypes of infections. Conclusion During the first year after discharge, 36% of patients with infection-related AF had a new hospital contact with AF. Infection-related AF was associated with increased risk of thromboembolic events compared with infection without AF and our results suggest that AF related to infection may merit treatment and follow-up similar to that of AF not related to infection. Open in new tab Download slide Open in new tab Download slide [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results